var title_f28_10_28832="Placentomegaly and ascites";
var content_f28_10_28832=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Longitudinal view of fetus with ascites and enlarged placenta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Svena Julien, MD and Charles Lockwood, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_10_28832=[""].join("\n");
var outline_f28_10_28832=null;
var title_f28_10_28833="Postop sled exstrophy";
var content_f28_10_28833=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The use of a sled for traction and immobilization after bladder exstrophy repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Laurence Baskin.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_10_28833=[""].join("\n");
var outline_f28_10_28833=null;
var title_f28_10_28834="Thoracic aneurysm PI";
var content_f28_10_28834=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F59752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F59752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Aneurysm of the thoracic aorta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 490px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A thoracic aortic aneurysm is a widening or dilation in the main artery that carries blood from the heart. Intact thoracic aortic aneurysms cause no health problems. However, large aneurysms can burst, or rupture, allowing excessive bleeding into the abdomen or chest. A ruptured aortic aneurysm is a medical emergency, and immediate treatment is needed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_10_28834=[""].join("\n");
var outline_f28_10_28834=null;
var title_f28_10_28835="Multiple NB metastases";
var content_f28_10_28835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Multiple neuroblastoma metastases",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 515px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MIBG scan of a newly diagnosed patient with multiple metastases. Arrows specifically demonstrate cranial and leg bone metastases as well as the primary adrenal tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Heidi V Russell, MD, Jason M Shohet, MD, and Jed G Nuchtern, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_10_28835=[""].join("\n");
var outline_f28_10_28835=null;
var title_f28_10_28836="L-carnitine: Patient drug information";
var content_f28_10_28836=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   L-carnitine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     see \"L-carnitine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     see \"L-carnitine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F187916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carnitine-300 [OTC];",
"     </li>",
"     <li>",
"      Carnitor&reg;;",
"     </li>",
"     <li>",
"      Carnitor&reg; SF;",
"     </li>",
"     <li>",
"      L-Carnitine [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F187917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Carnitor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691777",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat carnitine deficiencies.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702377",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to levocarnitine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698697",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are new or worse after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695871",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take during or after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694674",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Split the daily dose into 2 or 3 doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694292",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills. Mix with water and drink slowly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10799 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.76.133-0613BE51B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_10_28836=[""].join("\n");
var outline_f28_10_28836=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187916\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187917\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012307\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012306\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012311\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012312\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012314\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012309\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012310\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012315\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012316\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=related_link\">",
"      L-carnitine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=related_link\">",
"      L-carnitine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_10_28837="Vitiligo universal";
var content_f28_10_28837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Universal vitiligo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vitiligo. Extensive depigmentation. The residual normal pigmentation was treated with monobenzone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_10_28837=[""].join("\n");
var outline_f28_10_28837=null;
var title_f28_10_28838="Cyanocobalamin (vitamin B12): Drug information";
var content_f28_10_28838=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cyanocobalamin (vitamin B12): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/16/35077?source=see_link\">",
"    see \"Cyanocobalamin (vitamin B12): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/37/1622?source=see_link\">",
"    see \"Cyanocobalamin (vitamin B12): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F155136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ener-B&reg; [OTC];",
"     </li>",
"     <li>",
"      Nascobal&reg;;",
"     </li>",
"     <li>",
"      Twelve Resin-K [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F155180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vitamin, Water Soluble",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F155139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Recommended intake:",
"     </b>",
"     2.4 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pregnancy: 2.6 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lactation: 2.8 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      deficiency:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intranasal (Nascobal&reg;): 500 mcg in one nostril once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 250 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., deep SubQ: Initial: 30 mcg/day for 5-10 days; maintenance: 100-200 mcg/month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Pernicious anemia:",
"     </b>",
"     I.M., deep SubQ (administer concomitantly with folic acid if needed, 1 mg/day for 1 month): 100 mcg/day for 6-7 days; if improvement, administer same dose on alternate days for 7 doses, then every 3-4 days for 2-3 weeks; once hematologic values have returned to normal, maintenance dosage: 100 mcg/month.",
"     <b>",
"      Note:",
"     </b>",
"     Alternative dosing of 1000 mcg/day for 5 days (followed by 500-1000 mcg/month) has been used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic remission (without evidence of nervous system involvement):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intranasal (Nascobal&reg;): 500 mcg in one nostril once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 1000-2000 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., SubQ: 100-1000 mcg/month",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F155161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/37/1622?source=see_link\">",
"      see \"Cyanocobalamin (vitamin B12): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adequate intake:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     0-6 months: 0.4 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     7-12 months: 0.5 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Recommended intake:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-3 years: 0.9 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     4-8 years: 1.2 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     9-13 years: 1.8 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;14 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      deficiency:",
"     </b>",
"     I.M., deep SubQ: Dosage in children is not well established: 0.2 mcg/kg for 2 days, followed by 1000 mcg/day for 2-7 days, followed by 100 mcg/week for one month; for malabsorptive causes of B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency, monthly maintenance doses of 100 mcg have been recommended",
"     <b>",
"      or",
"     </b>",
"     as an alternative 100 mcg/day for 10-15 days, then once or twice weekly for several months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pernicious anemia:",
"     </b>",
"     I.M., deep SubQ (administer concomitantly with folic acid if needed, 1 mg/day for 1 month): 30-50 mcg/day for 2 or more weeks (to a total dose of 1000-5000 mcg), then follow with 100 mcg/month as maintenance dosage",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F155140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15795913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Use with caution; some formulations may also contain aluminum, which may accumulate in renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15795914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F155113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 1000 mcg/mL (1 mL, 10 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lozenge, oral: 50 mcg (100s); 100 mcg (100s); 250 mcg (100s, 250s); 500 mcg (100s, 250s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lozenge, sublingual: 500 mcg (100s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nascobal&reg;: 500 mcg/spray (2.3 mL) [contains benzalkonium chloride; delivers 8 doses]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, for buccal application/oral/sublingual:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Twelve Resin-K: 1000 mcg [gluten free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mcg, 100 mcg, 250 mcg, 500 mcg, 1000 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ener-B&reg;: 100 mcg, 500 mcg, 1000 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sublingual: 1000 mcg, 2500 mcg, 5000 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, timed release, oral: 1000 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ener-B&reg;: 1500 mcg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F155098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes nasal spray",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F155117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M./SubQ: I.M. or deep SubQ are preferred routes of administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intranasal: Nasal spray (Nascobal&reg;): Prior to initial dose, activate (prime) spray nozzle by pumping unit quickly and firmly until first appearance of spray, then prime twice more. The unit must be reprimed once immediately before each subsequent use. Administer 1 hour before or after ingestion of hot foods/liquids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Not recommended due to rapid elimination",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Not recommended due to variable absorption; however, oral therapy of 1000-2000 mcg/day has been effective for anemia if I.M./SubQ routes refused or not tolerated.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F155186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     NS, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Heparin, hydrocortisone sodium succinate, potassium chloride, vitamin B complex with C.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F155116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pernicious anemia; vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency due to dietary deficiencies or  malabsorption diseases, inadequate secretion of intrinsic factor, and inadequate utilization of B",
"     <sub>",
"      12",
"     </sub>",
"     (eg, during neoplastic treatment); increased B",
"     <sub>",
"      12",
"     </sub>",
"     requirements due to pregnancy, thyrotoxicosis, hemorrhage, malignancy, liver or kidney disease",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F155178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: CHF, peripheral vascular disorder, peripheral vascular thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, headache, hypoesthesia, incoordination, pain, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Itching, urticaria, exanthema (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, dyspepsia, glossitis, nausea, sore throat, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Polycythemia vera",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Abnormal gait, arthritis, back pain, myalgia, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, pulmonary edema, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis (parenteral) and infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F155120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cyanocobalamin, cobalt, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F155102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency for &gt;3 months results in irreversible degenerative CNS lesions; neurologic manifestations will not be prevented with folic acid unless vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     is also given. Spinal cord degeneration might also occur when folic acid used as a substitute for vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     in anemia prevention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Treatment of severe vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     megaloblastic anemia may result in severe hypokalemia, sometimes fatal, due to intracellular potassium shift upon anemia resolution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytosis: Treatment of severe vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     megaloblastic anemia may result in thrombocytosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Leber&rsquo;s disease: Use with caution in patients with Leber&rsquo;s disease patients; B",
"     <sub>",
"      12",
"     </sub>",
"     treatment may result in rapid optic atrophy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pernicious anemia: Appropriate use: I.M./SubQ routes are used to treat pernicious anemia; oral and intranasal administration are not indicated until hematologic remission and no signs of nervous system involvement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polycythemia vera: Vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency masks signs of polycythemia vera; vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     administration may unmask this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aluminum: Some parenteral products contain aluminum; use caution in patients with impaired renal function and neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Some products contain benzyl alcohol which has been associated with \"gasping syndrome\" in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intranasal administration: Efficacy in patients with nasal pathology or with other concomitant intranasal therapy has not been determined. Use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; I.V. administration: Avoid intravenous route; anaphylactic shock has occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Test dose: Intradermal test dose of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     is recommended for any patient suspected of cyanocobalamin sensitivity prior to intranasal or injectable administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F155106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May diminish the therapeutic effect of Cyanocobalamin. The expected hematologic response for the treatment of anemia may be opposed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: May decrease the serum concentration of Cyanocobalamin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F155133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Heavy consumption &gt;2 weeks may impair vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     absorption.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14207663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Water soluble vitamins cross the placenta. Absorption of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     may increase during pregnancy. Vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     requirements may be increased in pregnant women compared to nonpregnant women. Serum concentrations of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     are higher in the neonate at birth than the mother (IOM, 1998).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F155145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/compatible",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3869860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vitamin  B",
"     <sub>",
"      12",
"     </sub>",
"     is found in breast milk. Milk concentrations are similar to maternal serum concentrations and concentrations may be decreased in women who are vegetarians. Vitamin  B",
"     <sub>",
"      12",
"     </sub>",
"     requirements may be increased in nursing women compared to non-nursing women (IOM, 1998).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F155123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Strict vegetarian diets (eg, without eggs or dairy products) may result in vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F155122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (B12-Active Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (30): $6.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cyanocobalamin Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mcg/mL (1 mL): $3.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nascobal Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mcg/0.1 mL (1.3 mL): $394.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sublingual",
"     </b>",
"     (Cyanocobalamin Sublingual)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2500 mcg (50): $6.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Vitamin B-12 ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mcg (60): $5.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (VitaMelts Energy Vitamin B-12 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1500 mcg (60): $6.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Vitamin B-12 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg (100): $3.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mcg (100): $3.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mcg (100): $5.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mcg (100): $5.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F155111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     , hemoglobin, hematocrit, erythrocyte and reticulocyte count, folate and iron levels should be obtained prior to treatment; vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     and peripheral blood counts should be monitored 1 month after beginning treatment, then every 3-6 months thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Megaloblastic anemia: In addition to normal hematological parameters, serum potassium and platelet counts should be monitored during therapy",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F155114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Normal range of serum B",
"     <sub>",
"      12",
"     </sub>",
"     is 150-750 pg/mL; this represents 0.1% of total body content. Metabolic requirements are 2-5 mcg/day; years of deficiency required before hematologic and neurologic signs and symptoms are seen. Occasional patients with significant neuropsychiatric abnormalities may have no hematologic abnormalities and normal serum cobalamin levels, 200 pg/mL (SI: &gt;150 pmol/L), or more commonly between 100-200 pg/mL (SI: 75-150 pmol/L).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F155124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ambe 12 (LU);",
"     </li>",
"     <li>",
"      Ampavit (TH);",
"     </li>",
"     <li>",
"      Arcored (ID);",
"     </li>",
"     <li>",
"      B12 Ankermann (PL);",
"     </li>",
"     <li>",
"      B12 Latino (ES);",
"     </li>",
"     <li>",
"      Bedoc (GR);",
"     </li>",
"     <li>",
"      Bedodeka (IL);",
"     </li>",
"     <li>",
"      Bedoze (PT);",
"     </li>",
"     <li>",
"      Bedozil (BR);",
"     </li>",
"     <li>",
"      Behepan (SE);",
"     </li>",
"     <li>",
"      Betolvex (CH, DK, FI, NO, SE);",
"     </li>",
"     <li>",
"      Betolvex[inj.] (SE);",
"     </li>",
"     <li>",
"      Cianocobalamina B12 Davi (PT);",
"     </li>",
"     <li>",
"      Cincomil Bedoce (ES);",
"     </li>",
"     <li>",
"      Co Vitam B12 (ES);",
"     </li>",
"     <li>",
"      Cobalin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Cobamin Ophth Soln (HK);",
"     </li>",
"     <li>",
"      Creliverol-12 (PE);",
"     </li>",
"     <li>",
"      Cromatonbic B12 (ES);",
"     </li>",
"     <li>",
"      Cytamen (AU, GB, IE);",
"     </li>",
"     <li>",
"      Dobetin (IT, VE);",
"     </li>",
"     <li>",
"      Dodec (TR);",
"     </li>",
"     <li>",
"      Dolo-Neurobion Retard (MX);",
"     </li>",
"     <li>",
"      Ecovitamine B12 (FR);",
"     </li>",
"     <li>",
"      Isopto B12 (ES);",
"     </li>",
"     <li>",
"      Kiddi Pharmaton (MX);",
"     </li>",
"     <li>",
"      Lagavit B12 (AE, BB, BH, BM, BS, BZ, CY, EG, GY, IQ, IR, JM, JO, KW, LB, LY, NL, OM, PR, QA, SA, SR, SY, TT, YE);",
"     </li>",
"     <li>",
"      Ledoxina (MX);",
"     </li>",
"     <li>",
"      Lifaton B12 (ES);",
"     </li>",
"     <li>",
"      Mono Vitamine B12 (FR);",
"     </li>",
"     <li>",
"      Neurobene (CZ, HN);",
"     </li>",
"     <li>",
"      Norivite-12 (ZA);",
"     </li>",
"     <li>",
"      Noventabedoce (ES);",
"     </li>",
"     <li>",
"      Optovite B12 (ES);",
"     </li>",
"     <li>",
"      Permadoze (PT);",
"     </li>",
"     <li>",
"      Permadoze oral (PT);",
"     </li>",
"     <li>",
"      Reedvit 10000 (AR);",
"     </li>",
"     <li>",
"      Reticulogen (ES);",
"     </li>",
"     <li>",
"      Retidex B12 (ES);",
"     </li>",
"     <li>",
"      Rojamin (EC);",
"     </li>",
"     <li>",
"      Rubramin (PH);",
"     </li>",
"     <li>",
"      Sancoba (JP);",
"     </li>",
"     <li>",
"      Sorbevit B12 (ES);",
"     </li>",
"     <li>",
"      Tribedoce DX (MX);",
"     </li>",
"     <li>",
"      Vegevit B12 (PL);",
"     </li>",
"     <li>",
"      Vicapan N (DE);",
"     </li>",
"     <li>",
"      Vitalen (MX);",
"     </li>",
"     <li>",
"      Vitam-Doce (AR);",
"     </li>",
"     <li>",
"      Vitamin B!1!2 (HR, HU);",
"     </li>",
"     <li>",
"      Vitamin B!1!2 Lannacher (AT);",
"     </li>",
"     <li>",
"      Vitamin B12 Recip (SE);",
"     </li>",
"     <li>",
"      Vitamina B12-Ecar (CO);",
"     </li>",
"     <li>",
"      Vitamine B12-Dulcis (LU);",
"     </li>",
"     <li>",
"      Vitaminum B12 (PL);",
"     </li>",
"     <li>",
"      Vitarubin (CH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F155101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Coenzyme for various metabolic functions, including fat and carbohydrate metabolism and protein synthesis, used in cell replication and hematopoiesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F155119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Variable from the terminal ileum; requires the presence of calcium and gastric &ldquo;intrinsic factor&rdquo; to transfer the compound across the intestinal mucosa",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Principally stored in the liver and bone marrow, also stored in the kidneys and adrenals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Transcobalamins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Converted in tissues to active coenzymes, methylcobalamin and deoxyadenosylcobalamin; undergoes some enterohepatic recycling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Intranasal solution: Nascobal&reg;: 6.1% (relative to I.M.)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Andres E, Noel E, and Goichot B, &ldquo;Metformin-Associated Vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      Deficiency,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2002, 162(19):2251-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/10/28838/abstract-text/12390080/pubmed\" id=\"12390080\" target=\"_blank\">",
"        12390080",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goodman M, Chen XH, Daarwish D, &ldquo;Are U.S. Lower Normal B",
"      <sub>",
"       12",
"      </sub>",
"      Limits Too Low?,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1996, 44(10):1274-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/10/28838/abstract-text/8856015/pubmed\" id=\"8856015\" target=\"_blank\">",
"        8856015",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B",
"      </i>",
"      <sub>",
"       6",
"      </sub>",
"      <i>",
"       , Folate, Vitamin B",
"      </i>",
"      <sub>",
"       12",
"      </sub>",
"      <i>",
"       , Pantothenic Acid, Biotin and Choline",
"      </i>",
"      , Washington, DC: National Academy Press, 1998.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lane LA and Rojas-Fernandez C, &ldquo;Treatment of Vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      -Deficiency Anemia: Oral Versus Parenteral Therapy,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2002, 36(7-8):1268-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/10/28838/abstract-text/12086562/pubmed\" id=\"12086562\" target=\"_blank\">",
"        12086562",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenbaum J, Healton EB, Savage DG, et al, &ldquo;Neuropsychiatric Disorders Caused by Cobalamin Deficiency in the Absence of Anemia or Macrocytosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 318(26):1720-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/10/28838/abstract-text/3374544/pubmed\" id=\"3374544\" target=\"_blank\">",
"        3374544",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson Textbook of Pediatrics, 17th ed, Behrman RE, Kliegman RM, and Jenson HB, eds, Philadelphia, PA: WB Saunders Co, 2004.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oh R and Brown DL, &ldquo;Vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      Deficiency,&rdquo;",
"      <i>",
"       Am Fam Physician",
"      </i>",
"      , 2003, 67(5):979-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/10/28838/abstract-text/12643357/pubmed\" id=\"12643357\" target=\"_blank\">",
"        12643357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olszewski AJ, Szostak WB, Bialkowska M, et al, &ldquo;Reduction of Plasma Lipid and Homocysteine Levels by Pyridoxine, Folate, Cobalamin, Choline, Riboflavin, and Troxerutin in Atherosclerosis,&rdquo;",
"      <i>",
"       Atherosclerosis",
"      </i>",
"      , 1989, 75(1):1-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/10/28838/abstract-text/2930611/pubmed\" id=\"2930611\" target=\"_blank\">",
"        2930611",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rasmussen SA, Fernhoff PM, and Scanlon KS, &ldquo;Vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      Deficiency in Children and Adolescents,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2001, 138(1):10-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/10/28838/abstract-text/11148506/pubmed\" id=\"11148506\" target=\"_blank\">",
"        11148506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Regland B, Gottfries CG, and Lindstedt G, &ldquo;Dementia Patients With Low Serum Cobalamin Concentration: Relationship to Atrophic Gastritis,&rdquo;",
"      <i>",
"       Aging (Milano)",
"      </i>",
"      , 1992, 4(1):35-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/10/28838/abstract-text/1627675/pubmed\" id=\"1627675\" target=\"_blank\">",
"        1627675",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schjonsby H, &ldquo;Vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      Absorption and Malabsorption,&rdquo;",
"      <i>",
"       Gut",
"      </i>",
"      , 1989, 30(12):1986-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/10/28838/abstract-text/2693230/pubmed\" id=\"2693230\" target=\"_blank\">",
"        2693230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schnyder G, Roffi M, Flammer Y, et al, &ldquo;Effect of Homocysteine-Lowering Therapy With Folic Acid, Vitamin B12, and Vitamin B6 on Clinical Outcome After Percutaneous Coronary Intervention: The Swiss Heart Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(8):973-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/10/28838/abstract-text/12190367/pubmed\" id=\"12190367\" target=\"_blank\">",
"        12190367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silbergleit R and Lee DC, &ldquo;Bowel Obstruction and Radiopaque Vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      &ldquo;Pseudobezoar&rdquo;,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1995, 13(1):112-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/10/28838/abstract-text/7832937/pubmed\" id=\"7832937\" target=\"_blank\">",
"        7832937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9302 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-F1EFE81ED1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_10_28838=[""].join("\n");
var outline_f28_10_28838=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155136\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155180\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155139\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155161\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155140\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795913\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795914\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155113\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155098\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155117\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155186\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155116\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155178\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155120\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155102\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299104\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155106\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155133\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14207663\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155145\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3869860\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155123\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155122\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155111\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155114\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155124\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155101\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155119\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9302\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9302|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/16/35077?source=related_link\">",
"      Cyanocobalamin (vitamin B12): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/37/1622?source=related_link\">",
"      Cyanocobalamin (vitamin B12): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_10_28839="Adeno CA lung Light II";
var content_f28_10_28839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adenocarcinoma of the lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph of a hematoxylin and eosin-stained section of solid adenocarcinoma of the lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_10_28839=[""].join("\n");
var outline_f28_10_28839=null;
var title_f28_10_28840="Traveling with oxygen aboard commercial air carriers";
var content_f28_10_28840=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Traveling with oxygen aboard commercial air carriers",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/10/28840/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/10/28840/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/10/28840/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/10/28840/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/10/28840/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/10/28840/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/10/28840/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that over one billion passengers travel by air each year [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/1\">",
"     1",
"    </a>",
"    ]. Flying at a high altitude can induce significant hypoxemia in patients with underlying lung disease, despite pressurization of airliner cabins. A large number of air travelers have underlying medical conditions, including pulmonary disease, and are at risk for adverse cardiopulmonary effects related to oxygen desaturation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation of patients for potential in-flight hypoxemia and the prescription of supplemental oxygen for air travel are reviewed here. General assessment and counseling prior to air travel and the indications for and provision of long-term supplemental oxygen are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13737?source=see_link\">",
"     \"Patient assessment for air travel\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=see_link\">",
"     \"Long-term supplemental oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFECTS OF AIR TRAVEL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Physiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;As altitude increases, ambient air pressure decreases, leading to a decrease in the oxygen tension (also known as the partial pressure of oxygen) of inspired air. The inspired oxygen tension (PiO",
"    <sub>",
"     2",
"    </sub>",
"    ) can be determined by the equation:",
"   </p>",
"   <p>",
"    PiO",
"    <sub>",
"     2",
"    </sub>",
"    = FiO",
"    <sub>",
"     2",
"    </sub>",
"    x (Patm - PH",
"    <sub>",
"     2",
"    </sub>",
"    O)",
"   </p>",
"   <p>",
"    where FiO",
"    <sub>",
"     2",
"    </sub>",
"    is the fraction of inspired oxygen (0.21 in atmospheric air), Patm is the atmospheric pressure (760 mmHg at sea level), and PH",
"    <sub>",
"     2",
"    </sub>",
"    O is the partial pressure of water (47 mmHg at 37 degrees C). Reduction in the PiO",
"    <sub>",
"     2",
"    </sub>",
"    will decrease the alveolar partial pressure of oxygen (PAO",
"    <sub>",
"     2",
"    </sub>",
"    ). A lower PAO",
"    <sub>",
"     2",
"    </sub>",
"    impairs oxygen diffusion by decreasing the oxygen gradient from the alveolus to the artery. The net effect is a lower arterial partial pressure of oxygen (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ), which may reach the level of hypoxemia (",
"    <a class=\"graphic graphic_table graphicRef77616 \" href=\"UTD.htm?31/21/32092\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/4,6-8\">",
"     4,6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=see_link&amp;anchor=H14#H14\">",
"     \"Oxygenation and mechanisms of hypoxemia\", section on 'Reduced inspired oxygen tension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pressurization of the cabin on commercial airliners limits the decrease in air pressure, allowing the airplane or jet to cruise at altitudes up to 40,000 feet (12,192 m) without inducing extreme hypobaric stress in the passengers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/9\">",
"     9",
"    </a>",
"    ]. Regulatory government agencies, such as the Federal Aviation Administration, have requirements specifying that airliner cabins be pressurized to simulate an altitude (so&ndash;called cabin altitude) below 8000 feet (2438 m) and allow only brief diversions to a cabin altitude of 10,000 feet (3048 m) for safety (eg, to avoid adverse weather).",
"   </p>",
"   <p>",
"    At cabin altitudes between 5000 and 8000 feet, the inspired oxygen tension (PiO",
"    <sub>",
"     2",
"    </sub>",
"    ) is calculated to be between 108 and 122 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/10\">",
"     10",
"    </a>",
"    ]. The resulting PaO",
"    <sub>",
"     2",
"    </sub>",
"    varies due to individual variation in baseline lung function and the ventilatory response to hypoxia.",
"   </p>",
"   <p>",
"    Another consequence of the decrease in ambient pressure is that gas in trapped spaces (eg, paranasal sinuses, abdominal viscera, lung bullae, and pleural space) expands (",
"    <a class=\"graphic graphic_table graphicRef77616 \" href=\"UTD.htm?31/21/32092\">",
"     table 1",
"    </a>",
"    ). A potential consequence of the expansion of air within a bulla is tissue separation, causing a pneumothorax. Thus, in addition to the direct effects of decreased oxygen tension, hypoxemia may be caused by barotrauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with normal cardiorespiratory function typically experience a decrease in arterial partial pressure of oxygen (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ) from above 95 mmHg to between 53 and 75 mmHg when going from sea level to a cabin altitude of 8000 feet (2438 m) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. This change in PaO",
"    <sub>",
"     2",
"    </sub>",
"    is on the upper, flat portion of the oxyhemoglobin curve, so the decrease in oxygen saturation is only 3 to 4 percent.",
"   </p>",
"   <p>",
"    For patients who have a PaO",
"    <sub>",
"     2",
"    </sub>",
"    below 95 mmHg at sea level, the decrease in PaO",
"    <sub>",
"     2",
"    </sub>",
"    at a cabin altitude of 8000 feet (2438 m) is on the steeper portion of the oxyhemoglobin saturation curve (",
"    <a class=\"graphic graphic_figure graphicRef81216 \" href=\"UTD.htm?2/26/2479\">",
"     figure 1",
"    </a>",
"    ), so it will be associated with a greater fall in oxygen saturation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/11\">",
"     11",
"    </a>",
"    ]. As an example, a patient with chronic obstructive pulmonary disease (COPD) and a PaO",
"    <sub>",
"     2",
"    </sub>",
"    of 70 mmHg at sea level would be likely to have a decrease in PaO",
"    <sub>",
"     2",
"    </sub>",
"    to 53 mmHg and a decrease in oxyhemoglobin saturation to 84 percent at a cabin altitude of 8000 feet [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Air travelers are usually sedentary during flight, thus reducing the likelihood of symptoms associated with a lower PaO",
"    <sub>",
"     2",
"    </sub>",
"    . However, even modest exercise under hypobaric conditions may be associated with substantial worsening of hypoxemia. In a study of 24 patients with various lung diseases, more than 80 percent experienced a decrease in PaO",
"    <sub>",
"     2",
"    </sub>",
"    to less than 50 mmHg during exercise in a chamber simulating a cabin altitude of 8000 feet [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite this degree of hypoxemia, patients with COPD who are exposed to high-altitude for several days are unlikely to experience adverse clinical events [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/2,6,13-16\">",
"     2,6,13-16",
"    </a>",
"    ]. Most studies suggest that medical emergencies occur in approximately one in every 19,000 to 40,000 travel episodes and deaths are 100&ndash;fold less common (about one death per 3,200,000 travel episodes) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/2,13-16\">",
"     2,13-16",
"    </a>",
"    ]. One possible reason for the low morbidity associated with air travel is that patients compensate for decreased oxygenation by hyperventilating [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SCREENING FOR IN-FLIGHT HYPOXEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The British Thoracic Society (BTS) has issued guidelines for screening patients for potential hypoxemia during air travel (defined as an arterial partial pressure of oxygen [PaO",
"    <sub>",
"     2",
"    </sub>",
"    ] &lt;55 mmHg [7.3 kPa]) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. The guidelines employ initial pulse oximetry to identify individuals who are highly likely or unlikely to require supplemental oxygen, or need further assessment.",
"   </p>",
"   <p>",
"    The British Thoracic Society guidelines can be accessed at",
"    <a class=\"external\" href=\"file://www.brit-thoracic.org.uk/ClinicalInformation/AirTravel/AirTravelGuideline/tabid/118/Default.aspx\">",
"     www.brit-thoracic.org.uk/ClinicalInformation/AirTravel/AirTravelGuideline/tabid/118/Default.aspx",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344161516\">",
"    <span class=\"h2\">",
"     Initial assessment with pulse oximetry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of pulse oxygen saturation (SpO",
"    <sub>",
"     2",
"    </sub>",
"    ) is performed at sea level while the patient is resting and breathing room air (",
"    <a class=\"graphic graphic_table graphicRef57963 \" href=\"UTD.htm?36/33/37403\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a resting room air SpO",
"      <sub>",
"       2",
"      </sub>",
"      &gt;95 percent at sea level, it is unlikely that their PaO",
"      <sub>",
"       2",
"      </sub>",
"      will decrease below 55 mmHg at cruising altitude, so in-flight oxygen is generally not needed [",
"      <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with a resting room air SpO",
"      <sub>",
"       2",
"      </sub>",
"      &lt;92 percent at sea level are candidates for supplemental oxygen in-flight. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Determining the oxygen requirement'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with a resting room air SpO",
"      <sub>",
"       2",
"      </sub>",
"      between 92 and 95 percent at sea level are assessed for risk factors for in-flight hypoxemia to determine the need for further testing. These risk factors are discussed in the next section.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These guidelines reflect the observed safety of air travel, but are not absolute. For patients with known severe lung disease, the clinician may choose to obtain further testing despite a pulse oxygen saturation &gt;95 percent. As an example, a prospective study of patients with a variety of lung diseases found that 23 percent of those with a SpO",
"    <sub>",
"     2",
"    </sub>",
"    &gt;95 percent experienced a decrease in PaO",
"    <sub>",
"     2",
"    </sub>",
"    to below 50 mmHg (6.6 kPa) while breathing a hypoxic gas mixture that simulated airline cruising altitude [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/19\">",
"     19",
"    </a>",
"    ]. On the other hand, none of these patients developed significant respiratory distress in-flight. Thus, further studies are needed to validate the predictive value of pulse oximetry screening among patients with a variety of lung diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Indications for further evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have a resting SpO",
"    <sub>",
"     2",
"    </sub>",
"    between 92 and 95 percent at sea level AND a risk factor for in-flight hypoxemia are candidates for further assessment to predict their likely in-flight PaO",
"    <sub>",
"     2",
"    </sub>",
"    (",
"    <a class=\"graphic graphic_table graphicRef57963 \" href=\"UTD.htm?36/33/37403\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/18\">",
"     18",
"    </a>",
"    ]. Risk factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Previous dyspnea or chest pain during air travel",
"     </li>",
"     <li>",
"      Inability to walk 50 m without respiratory distress",
"     </li>",
"     <li>",
"      Hypercapnia",
"     </li>",
"     <li>",
"      Forced expiratory volume in one second (FEV1) &lt;50 percent of predicted",
"     </li>",
"     <li>",
"      Reduced diffusing capacity [",
"      <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Restrictive respiratory disease due to interstitial lung disease, chest wall abnormality, or respiratory muscle weakness",
"     </li>",
"     <li>",
"      Cerebrovascular or cardiac disease",
"     </li>",
"     <li>",
"      Exacerbation of chronic lung disease requiring hospitalization within the prior six weeks",
"     </li>",
"     <li>",
"      Pulmonary hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who have a resting SpO",
"    <sub>",
"     2",
"    </sub>",
"    between 92 and 95 percent at sea level and no risk factors for in-flight hypoxemia are generally not referred for further testing and do not require in-flight supplemental oxygen [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/18\">",
"     18",
"    </a>",
"    ]. For patients with known severe lung disease and one of the risk factors noted above, it may be reasonable to obtain further testing even when the resting SpO",
"    <sub>",
"     2",
"    </sub>",
"    is &gt;95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344161666\">",
"    <span class=\"h2\">",
"     Methods for predicting in-flight hypoxemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several methods, including the use of regression equations, hypoxia altitude simulation testing, and hypobaric chamber testing, have been used to predict in-flight arterial partial pressure of oxygen (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ), when the results of pulse oximetry are NOT conclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Regression equations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several regression equations have been developed to predict whether the in&ndash;flight PaO",
"    <sub>",
"     2",
"    </sub>",
"    of normal travelers or those with pulmonary disease will fall below 50 mmHg at 8000 feet (2438 m) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. However, the predictive value of these equations has not been fully validated and this is the least accurate method for predicting in-flight hypoxemia. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Comparing methods'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Depending on the equation used, values of the PaO",
"    <sub>",
"     2",
"    </sub>",
"    at ground level, forced expiratory volume in one second",
"    <span class=\"nowrap\">",
"     (FEV1)/forced",
"    </span>",
"    vital capacity (FVC) ratio (without bronchodilators), and diffusing capacity (DLCO) are needed. These studies are ideally performed when the subject is clinically stable and within several weeks prior to the actual travel date.",
"   </p>",
"   <p>",
"    An equation that uses arterial blood gas results at sea level to predict in-flight PaO",
"    <sub>",
"     2",
"    </sub>",
"    was developed by combining results of several international studies (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?21/47/22257?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/25\">",
"     25",
"    </a>",
"    ]. The data from 1750 healthy individuals and 40 patients with COPD were included.",
"   </p>",
"   <p>",
"    PaO",
"    <sub>",
"     2",
"    </sub>",
"    altitude = 1.59 + (0.98 x PaO",
"    <sub>",
"     2",
"    </sub>",
"    at sea level) + (0.0031 x altitude) - (0.000061 x PaO",
"    <sub>",
"     2",
"    </sub>",
"    at sea level x altitude) - (0.000065 x PaCO",
"    <sub>",
"     2",
"    </sub>",
"    at sea level x altitude) + (0.000000092 x altitude squared)",
"   </p>",
"   <p>",
"    According to this equation, a patient whose resting room air PaO",
"    <sub>",
"     2",
"    </sub>",
"    is 78 mmHg or less and PaCO",
"    <sub>",
"     2",
"    </sub>",
"    is 40 mmHg would be likely to have an in-flight PaO",
"    <sub>",
"     2",
"    </sub>",
"    under 50 mmHg.",
"   </p>",
"   <p>",
"    A separate equation has been proposed for predicting in-flight resting PaO",
"    <sub>",
"     2",
"    </sub>",
"    in patients with restrictive chest disease, although it has only been assessed in a small number of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/27\">",
"     27",
"    </a>",
"    ]. The equation was developed by using a hypobaric chamber to simulate exposure to an altitude of 8000 feet (2438 m) in 17 patients with a variety of restrictive diseases, including kyphoscoliosis, pulmonary fibrosis, and sequelae of pulmonary tuberculosis. The following equation was proposed:",
"   </p>",
"   <p>",
"    PaO",
"    <sub>",
"     2",
"    </sub>",
"    at 8000 feet (in kPa) = 0.74 + (0.39 x PaO",
"    <sub>",
"     2",
"    </sub>",
"    at sea level [in kPa]) + (0.033 x DLCO [diffusing capacity, percent predicted])",
"   </p>",
"   <p>",
"    In contrast to the previous equations, this equation expresses the PaO",
"    <sub>",
"     2",
"    </sub>",
"    at sea level in kilopascals (kPa). To convert the result from kPa into mmHg, multiply by 7.5. The validity of this equation would need to be validated in a larger study population before being widely used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hypoxia altitude simulation test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypoxia altitude simulation test (HAST, also known as high altitude simulation test or hypoxia inhalation test) involves inhalation of a mixture of nitrogen with oxygen at a concentration of 15.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/8,23,28,29\">",
"     8,23,28,29",
"    </a>",
"    ]. This oxygen concentration is chosen as it simulates the oxygen concentration that an individual would breathe at an in&ndash;flight cabin altitude of 8000 feet (2438 m). An alternate method for delivering a hypoxic gas mixture is to use a 35 percent Venturi mask with nitrogen as the driving gas [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/18\">",
"     18",
"    </a>",
"    ]. This will yield a 15 to 16 percent oxygen mixture.",
"   </p>",
"   <p>",
"    At the beginning of the HAST, a sample of arterial blood for measurement of PaO",
"    <sub>",
"     2",
"    </sub>",
"    and PaCO",
"    <sub>",
"     2",
"    </sub>",
"    is obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/29\">",
"     29",
"    </a>",
"    ]. The patient's pulse oxygen saturation and electrocardiogram are monitored continuously during the test. Nasal cannula are in place in case supplemental oxygen is needed. A 15.1 percent oxygen mixture is administered via a tight-fitting mask or mouthpiece. The patient is monitored closely for dyspnea, chest pain, or other change in symptoms or vital signs. Dyspnea can be monitored with use of the Borg scale (",
"    <a class=\"graphic graphic_table graphicRef63981 \" href=\"UTD.htm?15/10/15532\">",
"     table 3",
"    </a>",
"    ). If the pulse oximeter shows oxygen desaturation below 85 percent, an arterial blood gas sample is obtained for confirmation.",
"   </p>",
"   <p>",
"    If the oxygen saturation remains at 88 or above while breathing the hypoxic mixture, an arterial blood gas sample is obtained after 20 minutes (",
"    <a class=\"graphic graphic_table graphicRef54344 \" href=\"UTD.htm?22/63/23547\">",
"     table 4",
"    </a>",
"    ). If the PaO",
"    <sub>",
"     2",
"    </sub>",
"    at the end of the HAST is greater than 55 mmHg (7.4 kPa, approximately a SpO",
"    <sub>",
"     2",
"    </sub>",
"    of 88), supplemental oxygen is NOT needed for air travel. If the PaO",
"    <sub>",
"     2",
"    </sub>",
"    decreases to &lt;50 mmHg (6.6 kPa, approximately a SpO",
"    <sub>",
"     2",
"    </sub>",
"    of 85), supplemental oxygen is advised for future air travel. If the PaO",
"    <sub>",
"     2",
"    </sub>",
"    is 50 to 55 mmHg (6.6 to 7.4 kPa), the test is considered borderline and an additional arterial blood gas sample or pulse oxygen saturation is obtained during mild exertion (eg, walking) while breathing the hypoxic mixture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Hypobaric chamber",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have used a hypobaric chamber to simulate an airline cabin altitude of 8000 feet (2438 m) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/12,23,24,30-32\">",
"     12,23,24,30-32",
"    </a>",
"    ]. However, hypobaric chambers are predominantly used as a research tool due to their limited availability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Comparing methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minimal data is available to determine which method of predicting in-flight PaO",
"    <sub>",
"     2",
"    </sub>",
"    is optimal, as few studies compare the regression equations and hypoxia altitude simulation test with in-flight measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/28,33,34\">",
"     28,33,34",
"    </a>",
"    ]. However, the following observations can be made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of regression equations based on pulmonary function test results and measurement of the PaO",
"      <sub>",
"       2",
"      </sub>",
"      at sea level is most readily available, but least accurate.",
"     </li>",
"     <li>",
"      Inhalation of hypoxic gas mixtures (ie, high altitude simulation testing, or HAST) is less readily available, but probably more accurate than the use of regression equations.",
"     </li>",
"     <li>",
"      Measurement of PaO",
"      <sub>",
"       2",
"      </sub>",
"      under hypobaric conditions, either during actual ascent to altitude (eg, on a mountain or in an unpressurized aircraft) or in a hypobaric chamber is likely most accurate, but generally only available for research purposes [",
"      <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/23,24,30-32\">",
"       23,24,30-32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prediction of in-flight PaO",
"    <sub>",
"     2",
"    </sub>",
"    by inhalation of a hypoxic gas mixture was compared to prediction using mathematical equations in a retrospective study of 45 patients with COPD, interstitial lung disease, or cystic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/33\">",
"     33",
"    </a>",
"    ]. Inhalation of a hypoxic gas mixture predicted a higher in-flight PaO",
"    <sub>",
"     2",
"    </sub>",
"    than that predicted by any of the mathematical equations used. This suggests that the mathematical equations might lead to a prescription for in-flight supplemental oxygen therapy more often than actually necessary.",
"   </p>",
"   <p>",
"    A separate assessment of the accuracy of the 16 currently available equations for predicting in-flight PaO",
"    <sub>",
"     2",
"    </sub>",
"    was performed in 24 COPD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/34\">",
"     34",
"    </a>",
"    ]. None of the available equations performed ideally (ie, areas under the Receiver Operating Curve were all &lt;0.79). A high altitude simulation test was more accurate than any of the equations for assessing the need for in-flight supplemental oxygen among patients with COPD.",
"   </p>",
"   <p>",
"    In a study of 13 passengers with COPD, the pulse oximetric saturation during HAST was compared with results obtained during air travel [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/28\">",
"     28",
"    </a>",
"    ]. The mean desaturation during HAST was comparable to the mean in-flight desaturation. However, the nadir oxygen saturation was lower during flight than during the HAST (78 versus 84 percent, respectively). This discrepancy was attributed to activity during the flight.",
"   </p>",
"   <p>",
"    Additional research using larger, prospective studies with comparison of the estimated in-flight PaO",
"    <sub>",
"     2",
"    </sub>",
"    to the actual value is necessary before a predictive method can be clearly recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DISEASE-SPECIFIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the data on the effects of air travel on oxygenation comes from studies of patients with COPD. However, patients with other lung diseases (eg, cystic fibrosis, pulmonary hypertension, pulmonary lymphangioleiomyomatosis [LAM]) may have disease-specific issues related to air travel. In addition, the accuracy of methods to predict hypoxemia in-flight has not been well studied in these patient populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cystic fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cystic fibrosis tend to have few symptoms related to oxygen desaturation at altitude, possibly due to chronically lower oxygen saturation at sea level. An observational study evaluated oxygenation and lung function at an altitude of 8694 feet (2650 meters) in 36 patients with cystic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/35\">",
"     35",
"    </a>",
"    ]. A PaO",
"    <sub>",
"     2",
"    </sub>",
"    less than 50 mmHg at rest was observed in one-third at rest and in two-thirds during low level exercise (30 watts), the equivalent of walking down the aisle. None of the patients had symptoms at rest and only one patient experienced light-headedness with exercise, despite the hypoxemia. Patients with a baseline PaO",
"    <sub>",
"     2",
"    </sub>",
"    of 60 mmHg (8.0 kPa) or higher tolerated several hours of exposure to an altitude of 8694 feet without symptoms. However, patients with more severe airflow obstruction tended to have a greater degree of desaturation at altitude.",
"   </p>",
"   <p>",
"    The consequences of brief periods of asymptomatic hypoxemia in these relatively young patients without concomitant heart disease are not known. In the absence of clear data, the same guidelines for supplemental oxygen are used for patients with cystic fibrosis as for other patients. (See",
"    <a class=\"local\" href=\"#H344161516\">",
"     'Initial assessment with pulse oximetry'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7\">",
"     'Indications for further evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with cystic fibrosis who anticipate a long flight may also need to bring a portable, battery-powered nebulizer for administration of medication in-flight. The use a portable nebulizer in-flight often requires prior permission from the airline [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=see_link\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pulmonary hypertension may be at particular risk for in-flight hypoxemia, as a low inspired oxygen tension can trigger pulmonary artery vasoconstriction and exacerbate hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/21\">",
"     21",
"    </a>",
"    ]. The combination of exertion and low in-flight oxygen tension may lead to further oxygen desaturation.",
"   </p>",
"   <p>",
"    Minimal data are available to guide the clinician in determining whether air travel is safe for a patient with pulmonary hypertension. It has been suggested that patients with Class III and IV disease avoid air travel, and those with less severe disease undergo high altitude simulation testing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/10,21\">",
"     10,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of simulation testing, it may be reasonable to provide in-flight supplemental oxygen for those with a mean pulmonary artery (PA) pressure of 35 mmHg or higher or a systolic PA pressure of 50 mmHg or higher [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pulmonary lymphangioleiomyomatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pulmonary lymphangioleiomyomatosis (LAM) have a combination of airflow obstruction and abnormal gas transfer. In addition, they have an increased risk of spontaneous secondary pneumothorax. In an observational study of 327 women with LAM, in-flight dyspnea was reported in 14 percent and oxygen desaturation in 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/36\">",
"     36",
"    </a>",
"    ]. The frequency of pneumothorax was 2 percent per flight (10 events in 454 flights) and 4 percent per patient (10 events per 276 women who had flown).",
"   </p>",
"   <p>",
"    It remains unclear what to recommend for patients with LAM who plan to travel on commercial airlines. Air travel should probably be avoided in the presence of new or worsening respiratory symptoms, a history of pneumothorax without pleurodesis, or extensive subpleural bullous or cystic change on radiographic imaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/30/4586?source=see_link&amp;anchor=H18#H18\">",
"     \"Pulmonary lymphangioleiomyomatosis\", section on 'Air travel'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DETERMINING THE OXYGEN REQUIREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental oxygen is suggested for individuals whose in&ndash;flight resting arterial partial pressure of oxygen (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ) is predicted to be less than 50 to 55 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. This includes patients who require long-term oxygen therapy at baseline. Once it has been determined that the patient should have supplemental oxygen for air travel, the next step is to determine the supplemental oxygen concentration that will result in adequate protection against hypoxemia in flight.",
"   </p>",
"   <p>",
"    Actual flow rate requirements can be assessed using a method for hypoxic gas inhalation, such as that used for the high altitude simulation test (HAST) described above [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/29,37\">",
"     29,37",
"    </a>",
"    ]. Similar to the HAST, the patient breathes a hypoxic mixture of nitrogen with 15.1 percent oxygen, while their pulse oxygen saturation (SpO",
"    <sub>",
"     2",
"    </sub>",
"    ) is monitored. Supplemental oxygen is delivered through a nasal cannula. The oxygen flow rate required to maintain adequate oxygenation during flight can then be estimated by measuring SpO",
"    <sub>",
"     2",
"    </sub>",
"    or PaO",
"    <sub>",
"     2",
"    </sub>",
"    at different flow rates. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Hypoxia altitude simulation test'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If hypoxia altitude testing is not available, we suggest using an oxygen flow rate of 2",
"    <span class=\"nowrap\">",
"     L/minute,",
"    </span>",
"    based on the observation that this flow rate restored adequate oxygenation in patients whose pulse oxygen saturation (SpO",
"    <sub>",
"     2",
"    </sub>",
"    ) was below 90 percent during hypoxic altitude simulation testing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In one study, an oxygen flow rate of 2",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    was sufficient in 20 travelers with either obstructive or restrictive lung disease, although one patient with severe COPD required oxygen at 3",
"    <span class=\"nowrap\">",
"     L/minute",
"    </span>",
"    to achieve a SpO",
"    <sub>",
"     2",
"    </sub>",
"    over 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/38\">",
"     38",
"    </a>",
"    ]. Similarly, in a study that used hypoxic gas to simulate an altitude of 6,700 feet, supplemental oxygen via nasal cannula at 1.2 + 0.3",
"    <span class=\"nowrap\">",
"     L/minute",
"    </span>",
"    restored baseline oxygen saturation in 11 patients with COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No specific guidelines exist for patients who require long-term supplemental oxygen at sea level. These patients will likely need to increase their oxygen flow while at cruising altitude. Preferably, the liter flow requirements are determined by direct measurement in a hypoxia altitude simulation test, as described above [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/1\">",
"     1",
"    </a>",
"    ]. An alternative is to increase the oxygen flow 1 to 2",
"    <span class=\"nowrap\">",
"     L/minute",
"    </span>",
"    over baseline while in flight [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/1,29\">",
"     1,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PRACTICAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Federal Aviation Administration rules prohibit travelers from carrying their own oxygen tanks or liquid oxygen aboard commercial aircraft. Most patients can use a Department of Transportation approved battery-powered portable oxygen concentrator, as airlines landing in the United States are now required to allow use of these devices throughout the flight [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/39\">",
"     39",
"    </a>",
"    ]. Alternatively, some airlines provide oxygen that is supplied in an oxygen canister packaged in a flame proof \"super box\" [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approved portable oxygen concentrators (eg, Inogen One, Airsep Lifestyle, Devilbiss Healthcare iGo) are generally available for rental from oxygen supply companies. The concentrators provide up to 3",
"    <span class=\"nowrap\">",
"     L/minute",
"    </span>",
"    of continuous flow, or 6",
"    <span class=\"nowrap\">",
"     L/minute",
"    </span>",
"    of pulsed flow [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/39\">",
"     39",
"    </a>",
"    ]. Battery power is needed for operation, so patients typically need to bring enough 12-cell batteries for one and half times the anticipated duration of the flight.",
"   </p>",
"   <p>",
"    Permission to use oxygen supplied by the airline or a portable oxygen concentrator is required in advance of travel (10 days for some airlines), which means that the evaluation of supplemental oxygen requirements must be performed at least 10 days before actual travel [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/39\">",
"     39",
"    </a>",
"    ]. The traveler will require a clinician's letter specifying the underlying pulmonary condition, the prescribed liter flow, and whether supplemental oxygen is required just during flight or throughout the day (",
"    <a class=\"graphic graphic_figure graphicRef71862 \" href=\"UTD.htm?9/40/9856\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Airline practices about the availability and cost of in&ndash;flight oxygen are not standardized throughout the airline industry, so clinicians and patients may need to consult brochures and source documents for specific carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Practical details such as the interface (eg, mask or nasal cannula) and the liter flow options are likely to vary between carriers. Prospective oxygen-using travelers are advised to seek comparative, current information when planning a trip [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several web sites offer a list of current air carriers' policies regarding use of in-flight oxygen and allowable equipment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/39,40,43,44\">",
"     39,40,43,44",
"    </a>",
"    ]. In addition, the European Lung Foundation has compiled information on European airlines, whose rules and charges regarding in&ndash;flight oxygen may differ from those of American carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/43\">",
"     43",
"    </a>",
"    ]. Efforts are underway to devise uniform standards for the use of medical oxygen in airports and on commercial aircraft [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28840/abstract/41,45\">",
"     41,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Travelers should carry multiple copies of prescriptions for necessary medications, and an emergency supply of \"contingency\" medications (perhaps a course of an antibiotic and a systemic glucocorticoid, as appropriate). A list of clinicians in locations along the travel route is also helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TRAVELER RESOURCES",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Airline Oxygen Council of America.",
"      <a class=\"external\" href=\"file://www.airlineoxygencouncil.org/\">",
"       www.airlineoxygencouncil.org",
"      </a>",
"      (Accessed on May 10, 2010).",
"     </li>",
"     <li>",
"      European Lung Foundation. Air travel.",
"      <a class=\"external\" href=\"file://www.european-lung-foundation.org/4059-european-lung-foundation-elf-air-travel.htm\">",
"       file://www.european-lung-foundation.org/4059-european-lung-foundation-elf-air-travel.htm",
"      </a>",
"      (Accessed May 11, 2010).",
"     </li>",
"     <li>",
"      Alpha-1 Foundation.",
"      <a class=\"external\" href=\"file://www.alphaone.org/\">",
"       www.alphaone.org",
"      </a>",
"      (Accessed on May 11, 2010).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/22/33122?source=see_link\">",
"       \"Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite pressurization of airliner cabins, flying at a high altitude can induce significant hypoxemia in patients with underlying lung disease. Patients who are at risk of becoming hypoxemic are candidates for supplemental oxygen during the flight. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Effects of air travel'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial screening is performed by assessing pulse oxygen saturation (SpO",
"      <sub>",
"       2",
"      </sub>",
"      ) while the patient is at rest and breathing room air (",
"      <a class=\"graphic graphic_table graphicRef57963 \" href=\"UTD.htm?36/33/37403\">",
"       table 2",
"      </a>",
"      ). Patients who have a SpO",
"      <sub>",
"       2",
"      </sub>",
"      of 95 or higher at sea level are unlikely to have significant hypoxemia during air travel and generally do not need further testing.",
"     </li>",
"     <li>",
"      For patients with a SpO",
"      <sub>",
"       2",
"      </sub>",
"      &lt;92 percent at sea level, we suggest use of supplemental oxygen in-flight (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Screening for in-flight hypoxemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have a resting SpO",
"      <sub>",
"       2",
"      </sub>",
"      between 92 and 95 percent at sea level and no risk factors for in-flight hypoxemia generally do not need further testing (",
"      <a class=\"graphic graphic_table graphicRef57963 \" href=\"UTD.htm?36/33/37403\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Indications for further evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have a resting SpO",
"      <sub>",
"       2",
"      </sub>",
"      between 92 and 95 percent at sea level AND a risk factor for in-flight hypoxemia are candidates for further assessment to predict their likely in-flight PaO",
"      <sub>",
"       2",
"      </sub>",
"      (",
"      <a class=\"graphic graphic_table graphicRef57963 \" href=\"UTD.htm?36/33/37403\">",
"       table 2",
"      </a>",
"      ). For these patients, the preferred method for assessing the need for in-flight supplemental oxygen is high altitude simulation testing (HAST), when available. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Indications for further evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Hypoxia altitude simulation test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The HAST involves monitoring pulse oximetry and arterial blood gases during inhalation of a mixture of nitrogen and oxygen at a concentration of 15.1 percent oxygen for 20 minutes (",
"      <a class=\"graphic graphic_table graphicRef54344 \" href=\"UTD.htm?22/63/23547\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Hypoxia altitude simulation test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If HAST testing is not available, a regression equation, using results from spirometry, diffusion capacity,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      arterial blood gases, may help predict which patients need supplemental oxygen during air travel. However, the regression equations tend to overestimate the need for in-flight supplemental oxygen. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Regression equations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are predicted to require supplemental oxygen during air travel, the preferred method to determine the actual flow rate requirements is to use hypoxic gas inhalation, such as that used for the high altitude simulation test (HAST). If such testing is not available, we suggest using an oxygen flow rate of 2",
"      <span class=\"nowrap\">",
"       L/minute",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Determining the oxygen requirement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who require long-term supplemental oxygen at baseline, we suggest using an increased liter flow during air travel (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The predicted liter flow requirements may be determined by direct measurement during a HAST, as described above. An alternative is to increase the oxygen flow 1 to 2",
"      <span class=\"nowrap\">",
"       L/minute",
"      </span>",
"      over baseline while in flight. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Determining the oxygen requirement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supplemental oxygen may be derived from approved portable oxygen canisters or oxygen concentrators. Airlines landing in the United States are now required to allow use of portable oxygen concentrators throughout the flight. However, a prescription is needed from the clinician (",
"      <a class=\"graphic graphic_figure graphicRef71862 \" href=\"UTD.htm?9/40/9856\">",
"       figure 2",
"      </a>",
"      ) and prior approval is needed from the airline. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Practical considerations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     British Thoracic Society. Managing passengers with respiratory disease planning air travel file://www.brit-thoracic.org.uk/Portals/0/Clinical%20Information/Air%20Travel/Guidelines/FlightRevision04.pdf (Accessed on May 13, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/2\">",
"      DeHart RL. Health issues of air travel. Annu Rev Public Health 2003; 24:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/3\">",
"      Gendreau MA, DeJohn C. Responding to medical events during commercial airline flights. N Engl J Med 2002; 346:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/4\">",
"      Humphreys S, Deyermond R, Bali I, et al. The effect of high altitude commercial air travel on oxygen saturation. Anaesthesia 2005; 60:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/5\">",
"      Muhm JM, Rock PB, McMullin DL, et al. Effect of aircraft-cabin altitude on passenger discomfort. N Engl J Med 2007; 357:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/6\">",
"      Seccombe LM, Peters MJ. Oxygen supplementation for chronic obstructive pulmonary disease patients during air travel. Curr Opin Pulm Med 2006; 12:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/7\">",
"      Stoller JK. Travel for the technology-dependent individual. Respir Care 1994; 39:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/8\">",
"      Gong H Jr, Tashkin DP, Lee EY, Simmons MS. Hypoxia-altitude simulation test. Evaluation of patients with chronic airway obstruction. Am Rev Respir Dis 1984; 130:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/9\">",
"      Hampson NB, Kregenow DA, Mahoney AM, et al. Altitude exposures during commercial flight: a reappraisal. Aviat Space Environ Med 2013; 84:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/10\">",
"      Mohr LC. Hypoxia during air travel in adults with pulmonary disease. Am J Med Sci 2008; 335:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/11\">",
"      Silverman D, Gendreau M. Medical issues associated with commercial flights. Lancet 2009; 373:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/12\">",
"      Knutson, SW, Dillard, TA, Berg, BW, Mehm, WJ. Impact of exercise on severity of hypoxemia during altitude exposure. Chest 1994; 106:174S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/13\">",
"      Cummins RO, Chapman PJ, Chamberlain DA, et al. In-flight deaths during commercial air travel. How big is the problem? JAMA 1988; 259:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/14\">",
"      Cummins RO, Schubach JA. Frequency and types of medical emergencies among commercial air travelers. JAMA 1989; 261:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/15\">",
"      Speizer C, Rennie CJ 3rd, Breton H. Prevalence of in-flight medical emergencies on commercial airlines. Ann Emerg Med 1989; 18:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/16\">",
"      Skjenna OW, Evans JF, Moore MS, et al. Helping patients travel by air. CMAJ 1991; 144:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/17\">",
"      Aker&oslash; A, Christensen CC, Edvardsen A, Skj&oslash;nsberg OH. Hypoxaemia in chronic obstructive pulmonary disease patients during a commercial flight. Eur Respir J 2005; 25:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/18\">",
"      Ahmedzai S, Balfour-Lynn IM, Bewick T, et al. Managing passengers with stable respiratory disease planning air travel: British Thoracic Society recommendations. Thorax 2011; 66 Suppl 1:i1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/19\">",
"      Coker RK, Shiner RJ, Partridge MR. Is air travel safe for those with lung disease? Eur Respir J 2007; 30:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/20\">",
"      Kelly PT, Swanney MP, Stanton JD, et al. Supplemental oxygen effect on hypoxemia at moderate altitude in patients with COPD. Aviat Space Environ Med 2009; 80:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/21\">",
"      Luks AM. Can patients with pulmonary hypertension travel to high altitude? High Alt Med Biol 2009; 10:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/22\">",
"      Mortazavi A, Eisenberg MJ, Langleben D, et al. Altitude-related hypoxia: risk assessment and management for passengers on commerical aircraft. Aviat Space Environ Med 2003; 74:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/23\">",
"      Dillard TA, Moores LK, Bilello KL, Phillips YY. The preflight evaluation. A comparison of the hypoxia inhalation test with hypobaric exposure. Chest 1995; 107:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/24\">",
"      Dillard TA, Rosenberg AP, Berg BW. Hypoxemia during altitude exposure. A meta-analysis of chronic obstructive pulmonary disease. Chest 1993; 103:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/25\">",
"      Muhm JM. Predicted arterial oxygenation at commercial aircraft cabin altitudes. Aviat Space Environ Med 2004; 75:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/26\">",
"      Kelly PT, Swanney MP, Seccombe LM, et al. Predicting the response to air travel in passengers with non-obstructive lung disease: are the current guidelines appropriate? Respirology 2009; 14:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/27\">",
"      Christensen CC, Ryg MS, Refvem OK, Skj&oslash;nsberg OH. Effect of hypobaric hypoxia on blood gases in patients with restrictive lung disease. Eur Respir J 2002; 20:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/28\">",
"      Kelly PT, Swanney MP, Seccombe LM, et al. Air travel hypoxemia vs. the hypoxia inhalation test in passengers with COPD. Chest 2008; 133:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/29\">",
"      Dine CJ, Kreider ME. Hypoxia altitude simulation test. Chest 2008; 133:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/30\">",
"      Robson AG, Hartung TK, Innes JA. Laboratory assessment of fitness to fly in patients with lung disease: a practical approach. Eur Respir J 2000; 16:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/31\">",
"      Henry JN, Krenis LJ, Cutting RT. Hypoxemia during aeromedical evacuation. Surg Gynecol Obstet 1973; 136:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/32\">",
"      Dillard TA, Berg BW, Rajagopal KR, et al. Hypoxemia during air travel in patients with chronic obstructive pulmonary disease. Ann Intern Med 1989; 111:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/33\">",
"      Martin SE, Bradley JM, Buick JB, et al. Flight assessment in patients with respiratory disease: hypoxic challenge testing vs. predictive equations. QJM 2007; 100:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/34\">",
"      Bradi AC, Faughnan ME, Stanbrook MB, et al. Predicting the need for supplemental oxygen during airline flight in patients with chronic pulmonary disease: a comparison of predictive equations and altitude simulation. Can Respir J 2009; 16:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/35\">",
"      Fischer R, Lang SM, Br&uuml;ckner K, et al. Lung function in adults with cystic fibrosis at altitude: impact on air travel. Eur Respir J 2005; 25:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/36\">",
"      Pollock-BarZiv S, Cohen MM, Downey GP, et al. Air travel in women with lymphangioleiomyomatosis. Thorax 2007; 62:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/37\">",
"      Vohra KP, Klocke RA. Detection and correction of hypoxemia associated with air travel. Am Rev Respir Dis 1993; 148:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/38\">",
"      Cramer D, Ward S, Geddes D. Assessment of oxygen supplementation during air travel. Thorax 1996; 51:202.",
"     </a>",
"    </li>",
"    <li>",
"     Airline Oxygen Council of America. www.airlineoxygencouncil.org (Accessed on May 10, 2010).",
"    </li>",
"    <li>",
"     American Association for Respiratory Care. www.breathineasy.com (Accessed on May 11, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/41\">",
"      Lyznicki JM, Williams MA, Deitchman SD, et al. Medical oxygen and air travel. Aviat Space Environ Med 2000; 71:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28840/abstract/42\">",
"      Stoller JK, Hoisington E, Auger G. A comparative analysis of arranging in-flight oxygen aboard commercial air carriers. Chest 1999; 115:991.",
"     </a>",
"    </li>",
"    <li>",
"     European Lung Foundation. Air travel. www.european-lung-foundation.org/index.php?id=4059 (Accessed on May 11, 2010).",
"    </li>",
"    <li>",
"     Alpha-1 Foundation. www.alphaone.org (Accessed on May 11, 2010).",
"    </li>",
"    <li>",
"     U.S. Research and Special Programs Administration. Hazardous Materials: Transportation of Compressed Oxygen, Other Oxidizing Gases and Chemical Oxygen Generators on Aircraft [FR Doc. 04-17747]. Published August 4, 2004. Available online at: file://hazmat.dot.gov/regs/rules/final/69fr/69fr-47074.htm (Accessed on March 7, 2005).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1448 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-D8D1174216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_10_28840=[""].join("\n");
var outline_f28_10_28840=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFECTS OF AIR TRAVEL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SCREENING FOR IN-FLIGHT HYPOXEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H344161516\">",
"      Initial assessment with pulse oximetry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Indications for further evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H344161666\">",
"      Methods for predicting in-flight hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Regression equations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hypoxia altitude simulation test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Hypobaric chamber",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Comparing methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DISEASE-SPECIFIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cystic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pulmonary lymphangioleiomyomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DETERMINING THE OXYGEN REQUIREMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PRACTICAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TRAVELER RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1448\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1448|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/26/2479\" title=\"figure 1\">",
"      Hemoglobin oxygen dissociation curve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/40/9856\" title=\"figure 2\">",
"      O2 prescription air travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1448|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/21/32092\" title=\"table 1\">",
"      Gas properties at altitude",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/33/37403\" title=\"table 2\">",
"      Assessing O2 need inflight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/10/15532\" title=\"table 3\">",
"      Borg scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/63/23547\" title=\"table 4\">",
"      Hypoxia altitude test",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?21/47/22257?source=related_link\" title=\"calculator 1\">",
"      Calculator: In-Flight PaO2 Estimation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39274?source=related_link\">",
"      Cystic fibrosis: Overview of the treatment of lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=related_link\">",
"      Long-term supplemental oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=related_link\">",
"      Oxygenation and mechanisms of hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13737?source=related_link\">",
"      Patient assessment for air travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/22/33122?source=related_link\">",
"      Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/30/4586?source=related_link\">",
"      Pulmonary lymphangioleiomyomatosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_10_28841="Therapeutic use and major side effects of sotalol";
var content_f28_10_28841=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Therapeutic use and major side effects of sotalol",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/10/28841/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/10/28841/contributors\">",
"     Elsa-Grace Giardina, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/10/28841/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/10/28841/contributors\">",
"     Mark S Link, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/10/28841/contributors\">",
"     Hugh Calkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/10/28841/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/10/28841/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/10/28841/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    , a methanesulfonanilide, is a class III antiarrhythmic drug (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 1",
"    </a>",
"    ) that is used for the treatment of both atrial and ventricular arrhythmias.",
"   </p>",
"   <p>",
"    This topic will review the electrophysiology and mechanisms of action of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , and will discuss dosing, the different settings in which sotalol has been used as an antiarrhythmic drug, and major side effects. Recommendations for the role of sotalol in the treatment of atrial and ventricular arrhythmias are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link&amp;anchor=H7#H7\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Adjunctive therapy in patients with an ICD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ELECTROPHYSIOLOGY AND MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    consists of a racemic mixture of d and l isomers in an approximate ratio of 1:1; this mixture is often called dl-sotalol. The two isomers contribute to the unique antiarrhythmic properties of sotalol [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The d isomer prolongs repolarization by blocking IKr, the rapid component of the delayed rectifier potassium current that is responsible for phase 3 depolarization of the action potential (",
"      <a class=\"graphic graphic_figure graphicRef71390 \" href=\"UTD.htm?15/55/16253\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. This represents a class III effect. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link\">",
"       \"Myocardial action potential and action of antiarrhythmic drugs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The l isomer has two actions: it prolongs repolarization and it has beta blocking activity. The latter effect is dose-dependent, is not cardioselective, and is not associated with membrane stabilizing activity or intrinsic sympathomimetic activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Class III activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiarrhythmic activity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    is primarily mediated by its class III property (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 1",
"    </a>",
"    ), which results in prolongation of the monophasic action potential duration as well as lengthening of the effective refractory period (ERP) in the atria, atrioventricular (AV) node (as reflected by the AH interval), ventricles, and antegrade and retrograde bypass tracts [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/3,7-9\">",
"     3,7-9",
"    </a>",
"    ]. The prolongation of cardiac action potential duration does not appear to be related to concurrent beta blockade, since d-sotalol, which has little beta blocking activity, produces a similar delay in repolarization as l-sotalol [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The class III effect results from blockade of the rapid component of the delayed rectifier potassium current (IKr) that is responsible for phase 3 repolarization of the action potential (",
"    <a class=\"graphic graphic_figure graphicRef71390 \" href=\"UTD.htm?15/55/16253\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    does not affect either the resting potential or rapid phase 0 depolarization that is mediated by sodium entry into the cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    on the action potential duration shows",
"    <strong>",
"     reverse use dependence",
"    </strong>",
"    , which is seen with other class III antiarrhythmic drugs except for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . Reverse use dependence is defined as an inverse correlation between the heart rate and the QT interval [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/10\">",
"     10",
"    </a>",
"    ]. As a result, the QT interval is prolonged as the heart rate slows, which could explain the association between bradycardia and antiarrhythmic drug-induced torsades de pointes and the possible decrease in drug efficacy at higher heart rates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link&amp;anchor=H3#H3\">",
"     \"Acquired long QT syndrome\", section on 'Pathophysiology'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H23\">",
"     'Proarrhythmia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     d-Sotalol",
"    </span>",
"    &nbsp;&mdash;&nbsp;A preparation containing only the d isomer has been developed as a \"pure\" class III drug [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. However, in the SWORD trial of patients with a reduced left ventricular ejection fraction and either a recent MI or symptomatic heart failure and a remote MI, d-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    therapy, compared to placebo, was associated with a significant",
"    <strong>",
"     increase",
"    </strong>",
"    in mortality that was largely due to an increase in presumed arrhythmic deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/12\">",
"     12",
"    </a>",
"    ]. This observation suggests an important contribution from the beta blocking activity that is seen with dl-sotalol. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16217?source=see_link&amp;anchor=H20#H20\">",
"     \"Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction\", section on 'Sotalol'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Beta blockade",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    -induced beta blockade include an increased sinus cycle length (slowed heart rate), decreased AV nodal conduction and increased AV nodal refractoriness (prolonged PR interval) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Effects on the ECG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combined actions of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    produce a variety of changes in the electrocardiogram (ECG) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/3,13,14\">",
"     3,13,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because of its beta blocking activity,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      slows the sinus rate by about 25 percent and slightly prolongs the PR interval.",
"     </li>",
"     <li>",
"      The QRS duration is not altered, since ventricular conduction at normal sinus rates is unchanged [",
"      <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. This is thought to reflect a lack of effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      on the His-Purkinje (HV) interval [",
"      <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/3,8,15\">",
"       3,8,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The QT interval is prolonged in a dose-dependent fashion [",
"      <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/16\">",
"       16",
"      </a>",
"      ]. Since the QRS duration is not prolonged, the increase in QT interval results solely from delayed repolarization (ie, the JT interval) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. In a review of 114 patients given chronic oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      therapy, the average increase in QT interval was 80 and 91 msec with 320 and 640",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/13\">",
"       13",
"      </a>",
"      ]. However, the increase in QTc, which is corrected for heart rate, was less prominent (21 and 30 msec, respectively). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=see_link&amp;anchor=H7#H7\">",
"       \"Diagnosis of congenital long QT syndrome\", section on 'Correction for rate'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DOSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    should be individualized on the basis of therapeutic response and tolerance. Because of its beta blocking activity, sotalol should not be used in patients with uncontrolled asthma, sinus bradycardia, Mobitz II second degree AV block or third degree AV block (unless the patient is treated with a pacemaker), cardiogenic shock, or uncontrolled heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, because sotalol prolongs the QT interval, it should not be used in patients with congenital or acquired long QT syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bradycardic and proarrhythmic events can occur after the initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    therapy and with each upward dosing adjustment. As a result, sotalol should be initiated and doses increased in a hospital with facilities for cardiac rhythm monitoring and assessment. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Proarrhythmia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The frequency with which adverse cardiac events occur was illustrated in a retrospective study of 417 patients who underwent 597 drug trials for conversion of atrial fibrillation or for initiation of maintenance therapy after electrical cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/17\">",
"     17",
"    </a>",
"    ]. Among the 72 trials with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    (80 mg orally twice daily), adverse cardiac events occurred in 18 percent: bradyarrhythmias occurred in eight (11 percent), ventricular arrhythmias in two (2.8 percent), and QT prolongation in one (1.4 percent). The risk was greatest within the first 24 hours of therapy and in patients with a previous myocardial infarction.",
"   </p>",
"   <p>",
"    Similar findings were noted in a report of 120 patients who were admitted to the hospital for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    therapy for atrial arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/18\">",
"     18",
"    </a>",
"    ]. A complication occurred in 25 patients (21 percent), which triggered a change in therapy (eg, dose reduction or sotalol cessation) in 21. The most common complications were bradycardia in 20 (including a heart rate below",
"    <span class=\"nowrap\">",
"     40/min",
"    </span>",
"    in 13), excessive prolongation of the QT interval in eight, and new or increased ventricular arrhythmias in seven (including two cases of torsades de pointes). Complications occurred within the first three days in 22 of the patients (88 percent).",
"   </p>",
"   <p>",
"    After discharge, we generally have the patient return for an ECG at 48 to 72 hours and again at one and two weeks, looking for QT interval prolongation and bradyarrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Oral sotalol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended initial dose of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    in adults is 80 mg twice daily whether used for the treatment of ventricular arrhythmias or atrial fibrillation. If necessary, the initial dose can be increased gradually to 240 or 320",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Dose adjustments should be made at three day intervals so that steady-state plasma concentrations can be attained and the QT interval monitored. In a retrospective analysis, this standard approach was compared to initiating sotalol at 120 to 160 mg orally twice per day [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/19\">",
"     19",
"    </a>",
"    ]. The accelerated dosing regimen neither shortened hospitalization nor had any effect on treatment efficacy. Due to the marginally increased risk of cardiac and non-cardiac side effects with an accelerated regimen, we favor the traditional starting dose of 80 mg twice daily.",
"   </p>",
"   <p>",
"    A therapeutic response is usually obtained at a total daily dose of 160 to 320",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    given in two or three divided doses. Some patients with ventricular arrhythmias require doses as high as 480 to 640",
"    <span class=\"nowrap\">",
"     mg/day;",
"    </span>",
"    however, these doses are more likely to be associated with proarrhythmia and should only be considered when the potential benefit outweighs the increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Changing from other antiarrhythmic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before beginning",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , previous antiarrhythmic therapy should be withdrawn under careful monitoring for a minimum of two to three half-lives, if clinically possible. After discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , for example, sotalol should not be initiated until the QT interval has returned to normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    is primarily excreted unchanged in the urine, since it is not appreciably metabolized in the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/2\">",
"     2",
"    </a>",
"    ]. As a result, the elimination half-life is prolonged in patients with renal insufficiency. When sotalol is given for the treatment of ventricular arrhythmias, the dosing interval should be modified based upon the reduction in creatinine clearance:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &gt;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      &mdash; 12 hours",
"     </li>",
"     <li>",
"      30 to 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      &mdash; 24 hours",
"     </li>",
"     <li>",
"      10 to 29",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      &mdash; 36 to 48 hours",
"     </li>",
"     <li>",
"      &lt;10",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      &mdash; should be individualized",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with severe renal disease are at risk for potentially life-threatening ventricular arrhythmia even if low doses are used [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When used for the treatment of atrial fibrillation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    is considered contraindicated when the creatinine clearance is less than 40",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age alone does not alter the pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    . However, impaired renal function in older patients can increase the elimination half-life, resulting in drug accumulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    in children have not been established. The manufacturer's dosing recommendations for children more than two years of age is 30",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per dose, which is given three times daily. For infants and children &le;2 years of age, the manufacturer recommends a dosing reduction based upon an age factor determined from a graph. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     \"Sotalol: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dose can be increased gradually, if necessary, to a maximum of 60",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per dose, which is given three times daily. There should be at least 36 hours between dose increments to permit attainment of a new steady-state and to monitor the clinical response, heart rate, and QT interval.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    is extremely limited in pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7674?source=see_link\">",
"     \"Ventricular arrhythmias during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Intravenous sotalol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , which is not available in the United States, has primarily been used to terminate supraventricular tachyarrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. It has also been used to terminate spontaneous sustained ventricular tachycardia and to suppress inducible ventricular tachyarrhythmia during electrophysiology study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The usual dose is 1.5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    which is given slowly over 10 minutes. However, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    appears to be less effective in converting atrial fibrillation or atrial flutter than intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef51703 \" href=\"UTD.htm?23/17/23837\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link&amp;anchor=H8701836#H8701836\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\", section on 'Sotalol'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     QT interval prolongation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be given to patients with congenital or acquired long QT syndrome, unless the cause can be reversed, because of the risk of further QT interval prolongation and proarrhythmia, particularly torsades de pointes. A number of drugs can prolong the QT interval, including antiarrhythmic drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    , and the other class III agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"     table 2",
"    </a>",
"    ). All predispose to torsades de pointes except for amiodarone. Hypokalemia and hypomagnesemia are additional risk factors. Because of reverse use dependence, QT prolongation is more likely in patients with a bradyarrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Class III activity'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H23\">",
"     'Proarrhythmia'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CLINICAL INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    is used for the treatment of documented ventricular arrhythmias (ie, sustained ventricular tachycardia) that, in the judgment of the clinician are life-threatening, and for the maintenance of normal sinus rhythm in patients with symptomatic atrial fibrillation and atrial flutter who are currently in sinus rhythm.",
"   </p>",
"   <p>",
"    What follows is a brief review of the major settings in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    is given with links to the topic reviews in which the role of sotalol therapy is discussed in detail.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Ventricular arrhythmias",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       Sotalol",
"      </a>",
"      can prevent recurrence of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/13,27-29\">",
"       13,27-29",
"      </a>",
"      ]. However, sotalol is generally less effective than an implantable cardioverter-defibrillator (ICD); this difference is primarily seen in patients with a left ventricular ejection fraction &le;35 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. Thus, the main settings in which antiarrhythmic drugs are used as primary therapy are in patients who do not want or are not candidates for an ICD (eg, due to marked comorbidities or end-stage heart failure that make death likely). More often, antiarrhythmic drugs are given as adjunctive therapy to an ICD to reduce the frequency of appropriate shocks or of inappropriate shocks due to supraventricular arrhythmias. Although sotalol reduces both recurrent arrhythmia and the frequency of ICD shocks [",
"      <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/32\">",
"       32",
"      </a>",
"      ], sotalol is typically second-line therapy to empiric",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"       \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link&amp;anchor=H7#H7\">",
"       \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Adjunctive therapy in patients with an ICD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       Sotalol",
"      </a>",
"      is highly effective in patients with arrhythmogenic right ventricular cardiomyopathy who have either inducible or noninducible non-life-threatening VT; in contrast, other antiarrhythmic drugs have little efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/33\">",
"       33",
"      </a>",
"      ]. Thus, initial therapy with sotalol is a reasonable option for many such patients. For those that do not respond to sotalol, response to other drugs is unlikely, and consideration should be given to nonpharmacologic therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy\", section on 'Antiarrhythmic drugs'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Atrial arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the class III and beta blocking activity of dl-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    contribute to its use in the treatment of atrial arrhythmias, mostly atrial fibrillation (AF).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       Sotalol",
"      </a>",
"      can promote maintenance of sinus rhythm after cardioversion in patients with AF. It appears to be as effective as and less toxic than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      , as effective as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      , but less effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/34\">",
"       34",
"      </a>",
"      ]. The main indication for sotalol, if a rhythm control strategy is chosen, is in patients with underlying coronary heart disease (",
"      <a class=\"graphic graphic_algorithm graphicRef83173 \" href=\"UTD.htm?35/57/36766\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"       \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In comparison, oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      has limited efficacy for pharmacologic cardioversion of AF to sinus rhythm [",
"      <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/35\">",
"       35",
"      </a>",
"      ] and, where available, intravenous sotalol is less effective than other drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link&amp;anchor=H8701755#H8701755\">",
"       \"Restoration of sinus rhythm in atrial fibrillation\", section on 'Antiarrhythmic drugs used in cardioversion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       Sotalol",
"      </a>",
"      appears to be effective for the prevention of AF after cardiac surgery (eg, coronary artery bypass graft or valve surgery) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/36\">",
"       36",
"      </a>",
"      ]. In a meta-analysis of 15 studies involving sotalol for the prevention of AF after cardiac surgery, sotalol was significantly more effective in preventing AF than no treatment, placebo, or beta blockers, and it was equally as effective as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/37\">",
"       37",
"      </a>",
"      ]. Recommendations about the choice of a particular agent for the prevention of AF after cardiac surgery are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=see_link\">",
"       \"Atrial fibrillation and flutter after cardiac surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the DAPHNE trial 137 patients with the brady-tachycardia form of sinus node disease were treated with a dual chamber rate adaptive pacemaker and then randomly assigned to either beta blockers (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      ) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/38\">",
"       38",
"      </a>",
"      ]. After 12 months, 29 percent of patients were free from atrial arrhythmias recurrences in both groups. Similarly, there was no difference in the rates of cardioversion or hospitalization, both of which were lower in both groups in the 12 months after therapy compared to the 12 months before therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Fetal arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal tachycardia is a serious condition for which treatment should be initiated, especially in the presence of hydrops fetalis. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    for fetal tachycardia was evaluated in 21 fetuses with atrial flutter, supraventricular tachycardia, or ventricular tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/39\">",
"     39",
"    </a>",
"    ]. Sotalol restored sinus rhythm in 8 of 10 fetuses with atrial flutter and in 6 of 10 with supraventricular tachycardia. However, the fetal mortality rate was 19 percent and occurred primarily in those with supraventricular tachycardia.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    should be considered a drug of choice to treat fetal atrial flutter; however, the high mortality in those with supraventricular tachycardia suggests that the utility of sotalol therapy is limited for the treatment of this arrhythmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MAJOR SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    is generally well tolerated. It has been estimated that sotalol is discontinued because of side effects in approximately 15 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/3,40\">",
"     3,40",
"    </a>",
"    ]. The major causes for cessation of therapy are fatigue (4 percent), bradycardia, dyspnea, proarrhythmia (each 3 percent), and dizziness and asthenia (each 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/3\">",
"     3",
"    </a>",
"    ]. However, some of these side effects, such as dizziness, fatigue, and anxiety, may not be more common than with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/32\">",
"     32",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    The potential for cardiac toxicity is clearly of greatest concern. Bradycardic and proarrhythmic events can occur after the initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    therapy and with each upward dosing adjustment. As a result, sotalol should be initiated and doses increased in a hospital with facilities for cardiac rhythm monitoring and assessment. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Hospitalization'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Cardiac toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two major cardiac side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    are proarrhythmia, most often torsades de pointes (TdP), and bradycardia. In addition, the beta blocking activity of sotalol can cause new or worsened heart failure.",
"   </p>",
"   <p>",
"    The arrhythmic and bradycardic complications often occur within the first three days after the initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    therapy and with each upward dosing adjustment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. As a result, sotalol should be initiated and doses increased in a hospital with facilities for cardiac rhythm monitoring and assessment. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Hospitalization'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Proarrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    , like other class III drugs, has the potential to be arrhythmogenic due to marked prolongation of the duration of the action potential that is manifested on the surface ECG by prolongation of the QT interval [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/2,41\">",
"     2,41",
"    </a>",
"    ]. As mentioned above, this effect is mediated by blockade of IKr, the rapid component of the delayed rectifier potassium current that is responsible for phase 3 depolarization of the action potential (",
"    <a class=\"graphic graphic_figure graphicRef71390 \" href=\"UTD.htm?15/55/16253\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Class III activity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    At standard doses between 160 and 640",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    increases by QT interval by 40 to 100 msec [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/2\">",
"     2",
"    </a>",
"    ]. The maximum recommended QTc interval on sotalol is 500 to 520 msec [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/2,3,34\">",
"     2,3,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    on the action potential duration shows",
"    <strong>",
"     reverse use dependence",
"    </strong>",
"    , which is seen with other class III antiarrhythmic drugs except for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . Reverse use dependence is defined as an inverse correlation between the heart rate and the QT interval [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/10\">",
"     10",
"    </a>",
"    ]. As a result, the QT interval is prolonged as the heart rate slows, which could explain the association between bradycardia and antiarrhythmic drug-induced torsades de pointes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link&amp;anchor=H3#H3\">",
"     \"Acquired long QT syndrome\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most important clinical manifestation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    -induced proarrhythmia is torsades de pointes, characterized by a \"twisting\" of the peaks of the QRS complexes around the isoelectric line of the ECG (",
"    <a class=\"graphic graphic_waveform graphicRef53891 \" href=\"UTD.htm?42/23/43380\">",
"     waveform 1",
"    </a>",
"    ). Triggered activity caused by early afterdepolarizations is thought to be responsible for the induction of this arrhythmia, which is most likely to occur in patients with prolongation of the QT interval.",
"   </p>",
"   <p>",
"    The reported risk of TdP has varied from 1 to 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/32,40,42\">",
"     32,40,42",
"    </a>",
"    ]. The incidence of and risk factors for TdP were best addressed in a 1996 review of 3135 patients who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    for sustained VT or VF (41 percent) or non-life-threatening arrhythmias such as ventricular premature beats, atrial fibrillation, nonsustained VT, or paroxysmal supraventricular tachycardia (59 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall rate of TdP was 2.5 percent at a median follow-up of 164 days. However, a number of groups at significantly increased risk were identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       Sotalol",
"      </a>",
"      dose above 320",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (3.7 versus 1.8 and 0.1 percent at doses of 161 to 320",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and &le;160",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      respectively).",
"     </li>",
"     <li>",
"      Serum creatinine above 1.4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [124",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      in women and 1.6",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [141",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      in men (5.1 versus 2.2 percent).",
"     </li>",
"     <li>",
"      Sustained",
"      <span class=\"nowrap\">",
"       VT/VT",
"      </span>",
"      as the presenting arrhythmia (4.5 versus 1.1 percent with other arrhythmias such as atrial fibrillation).",
"     </li>",
"     <li>",
"      History of heart failure (5.0 versus 1.7 percent without heart failure) or coronary heart disease (3.1 versus 1.9 percent).",
"     </li>",
"     <li>",
"      Female gender (4.1 versus 1.9 percent in men). The gender difference was independent of dose-related bradycardic responses and was similar in women greater than 50 and &le;50 years of age, which suggests that estrogen may not be responsible for the increased risk in women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An increase in risk in females has also been noted with TdP due to other antiarrhythmic drugs, noncardiac drugs, and the congenital long QT syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. In each of these settings, females constitute approximately 70 percent of affected patients. Compared to males, females have a longer corrected QT interval and a greater response to drugs that block IKr, potentiating the development of TdP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link&amp;anchor=H10#H10\">",
"     \"Acquired long QT syndrome\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link&amp;anchor=H2157420#H2157420\">",
"     \"Clinical features of congenital long QT syndrome\", section on 'Age and sex'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are also general predisposing factors such as bradycardia, which is thought to result from reverse use dependence in which the QT interval is prolonged as the heart rate slows, and other factors that prolong the baseline QT interval such as hypokalemia, hypomagnesemia, and the concomitant use of other drugs that prolong the QT interval, including antiarrhythmic drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    , and the other class III agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"     table 2",
"    </a>",
"    ). All of these drugs predispose to torsades de pointes except for amiodarone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link&amp;anchor=H6#H6\">",
"     \"Major side effects of amiodarone\", section on 'Cardiac toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Bradycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    has the potential to cause all of the rhythm effects induced by beta blockade, including sinus bradycardia and atrioventricular block. Bradyarrhythmias, mostly sinus bradycardia, occur in approximately 10 to 15 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/2,3,17,18,32,40\">",
"     2,3,17,18,32,40",
"    </a>",
"    ]. In comparison, sinus node arrest and second or third degree heart block occur in &le;1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/3,40\">",
"     3,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , particularly for ventricular arrhythmias, have underlying cardiac disease. Fortunately, impairment of myocardial contractility in patients treated with sotalol is less than might be expected with a beta blocker. Most patients have no significant decrease in left ventricular ejection fraction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/2\">",
"     2",
"    </a>",
"    ], and it has been estimated that clinically significant heart failure aggravation occurs in only 1.5 to 3 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/34,40,47\">",
"     34,40,47",
"    </a>",
"    ]. The risk is greater in patients with a prior history of heart failure, particularly those with a baseline ejection fraction of &lt;30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/3,4,40,42\">",
"     3,4,40,42",
"    </a>",
"    ]. In the review of 3135 patients cited above, the incidence to TdP was much higher in patients with heart failure (5.0 versus 1.7 percent without heart failure) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the concern related to the safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    in patients with heart failure,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is generally preferred for the treatment of ventricular arrhythmias and for maintenance of sinus rhythm in atrial fibrillation when pharmacologic therapy is given. However, sotalol safely reduces the frequency of recurrent arrhythmia and appropriate shocks in patients with an implantable cardioverter-defibrillator [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link\">",
"     \"Atrial fibrillation in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In comparison to dl-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , d-sotalol has only class III antiarrhythmic action and is devoid of beta blocking activity. When given intravenously to patients with heart failure, d-sotalol exerts no clinically important acute hemodynamic effects even at doses that prolong the QT interval [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/48\">",
"     48",
"    </a>",
"    ]. However, in patients with left ventricular dysfunction due to a recent or remote myocardial infarction, d-sotalol increases mortality, presumably due to arrhythmic death [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    should not be used in patients with uncontrolled asthma, sinus bradycardia, Mobitz II second degree AV block and third degree AV block, congenital long QT syndrome, acquired long QT syndrome (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"     table 2",
"    </a>",
"    ), cardiogenic shock, or uncontrolled heart failure. In addition, it should be used with caution in patients with reduced renal function, since decreased clearance can result in drug accumulation and possible proarrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been stated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    should not be given with class IA antiarrhythmic drugs (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    ) because these drugs may also prolong refractoriness and the combination would further increase the propensity for proarrhythmia. Data exists, however, suggesting that the combination of low dose sotalol and a class IA agent is very effective in preventing the induction of ventricular tachycardia and the spontaneous recurrence of arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/49\">",
"     49",
"    </a>",
"    ]. In a study of 32 patients, for example, this combination markedly prolonged ventricular refractoriness (especially at higher heart rates), thereby eliminating the \"reverse use dependency\" (a reduction in refractoriness as heart rate increases) observed when sotalol is administered as a sole agent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/10/28841/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10900382\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       Sotalol",
"      </a>",
"      consists of a racemic mixture of d and l isomers in an approximate ratio of 1:1. The two isomers contribute to the unique antiarrhythmic properties of sotalol, with d isomer prolonging repolarization by blocking the rapid component of the delayed rectifier potassium current that is responsible for phase 3 depolarization of the action potential, while the l isomer both prolongs repolarization and has beta blocking activity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Electrophysiology and mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      on the action potential duration shows",
"      <strong>",
"       reverse use dependence",
"      </strong>",
"      , which is seen with other class III antiarrhythmic drugs, except for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      . Reverse use dependence is defined as an inverse correlation between the heart rate and the QT interval. As a result, the QT interval is prolonged as the heart rate slows, with an associated risk of drug-induced torsades de pointes and a possible decrease in drug efficacy at higher heart rates. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Class III activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bradycardic and proarrhythmic events occur in up to 20 percent of patients after the initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      therapy and with each upward dosing adjustment. As a result, sotalol should be initiated and doses increased in a hospital with facilities for cardiac rhythm monitoring and assessment. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The recommended initial dose of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      in adults is 80 mg twice daily whether used for the treatment of ventricular arrhythmias or atrial fibrillation. If necessary, the initial dose can be increased gradually to a total daily dose of 240 mg or 320 mg. Dose adjustments should be made at three day intervals so that steady-state plasma concentrations can be attained and the QT interval monitored. The dosing interval requires modification in patients with impaired renal function and reduced creatinine clearance. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Oral sotalol'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Renal insufficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       Sotalol",
"      </a>",
"      should",
"      <strong>",
"       not",
"      </strong>",
"      be given to patients with congenital or acquired long QT syndrome unless the cause can be reversed because of the risk of further QT interval prolongation and proarrhythmia, particularly torsades de pointes. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'QT interval prolongation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      is used for the treatment of ventricular arrhythmias (ie, sustained ventricular tachycardia) that are potentially life-threatening and for the maintenance of normal sinus rhythm in patients with symptomatic atrial fibrillation and atrial flutter who are currently in sinus rhythm. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Clinical indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       Sotalol",
"      </a>",
"      is generally well tolerated, being discontinued because of side effects in only approximately 15 percent of patients. The major causes for cessation of therapy are fatigue, bradycardia, dyspnea, proarrhythmia, dizziness and asthenia. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Major side effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/1\">",
"      Kato R, Ikeda N, Yabek SM, et al. Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics. J Am Coll Cardiol 1986; 7:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/2\">",
"      Hohnloser SH, Woosley RL. Sotalol. N Engl J Med 1994; 331:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/3\">",
"      Anderson JL, Prystowsky EN. Sotalol: An important new antiarrhythmic. Am Heart J 1999; 137:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/4\">",
"      Singh BN. Sotalol: Current Status and Expanding Indications. J Cardiovasc Pharmacol Ther 1999; 4:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/5\">",
"      Numaguchi H, Mullins FM, Johnson JP Jr, et al. Probing the interaction between inactivation gating and Dd-sotalol block of HERG. Circ Res 2000; 87:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/6\">",
"      Sanguinetti MC, Jurkiewicz NK. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990; 96:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/7\">",
"      Brodsky M, Saini R, Bellinger R, et al. Comparative effects of the combination of digoxin and dl-sotalol therapy versus digoxin monotherapy for control of ventricular response in chronic atrial fibrillation. dl-Sotalol Atrial Fibrillation Study Group. Am Heart J 1994; 127:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/8\">",
"      Nademanee K, Feld G, Hendrickson J, et al. Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. Circulation 1985; 72:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/9\">",
"      Mitchell LB, Wyse DG, Duff HJ. Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome. Circulation 1987; 76:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/10\">",
"      Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990; 81:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/11\">",
"      Hohnloser SH, Meinertz T, Stubbs P, et al. Efficacy and safety of d-sotalol, a pure class III antiarrhythmic compound, in patients with symptomatic complex ventricular ectopy. Results of a multicenter, randomized, double-blind, placebo-controlled dose-finding study. The d-Sotalol PVC Study Group. Circulation 1995; 92:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/12\">",
"      Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996; 348:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/13\">",
"      Anastasiou-Nana MI, Gilbert EM, Miller RH, et al. Usefulness of d, I sotalol for suppression of chronic ventricular arrhythmias. Am J Cardiol 1991; 67:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/14\">",
"      Creamer JE, Nathan AW, Shennan A, Camm AJ. Acute and chronic effects of sotalol and propranolol on ventricular repolarization using constant-rate pacing. Am J Cardiol 1986; 57:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/15\">",
"      Touboul P, Atallah G, Kirkorian G, et al. Clinical electrophysiology of intravenous sotalol, a beta-blocking drug with class III antiarrhythmic properties. Am Heart J 1984; 107:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/16\">",
"      Wang T, Bergstrand RH, Thompson KA, et al. Concentration-dependent pharmacologic properties of sotalol. Am J Cardiol 1986; 57:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/17\">",
"      Maisel WH, Kuntz KM, Reimold SC, et al. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med 1997; 127:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/18\">",
"      Chung MK, Schweikert RA, Wilkoff BL, et al. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J Am Coll Cardiol 1998; 32:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/19\">",
"      Kim RJ, Juriansz GJ, Jones DR, et al. Comparison of a standard versus accelerated dosing regimen for D,L-sotalol for the treatment of atrial and ventricular dysrhythmias. Pacing Clin Electrophysiol 2006; 29:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/20\">",
"      Rizza C, Valderrabano M, Singh BN. Recurrent Torsades de Pointes After Sotalol Therapy for Symptomatic Paroxysmal Atrial Fibrillation in a Patient with End-Stage Renal Disease. J Cardiovasc Pharmacol Ther 1999; 4:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/21\">",
"      Reiffel JA, Appel G. Importance of QT interval determination and renal function assessment during antiarrhythmic drug therapy. J Cardiovasc Pharmacol Ther 2001; 6:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/22\">",
"      Sung RJ, Tan HL, Karagounis L, et al. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group. Am Heart J 1995; 129:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/23\">",
"      Vos MA, Golitsyn SR, Stangl K, et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart 1998; 79:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/24\">",
"      Reisinger J, Gatterer E, Heinze G, et al. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998; 81:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/25\">",
"      Ho DS, Zecchin RP, Richards DA, et al. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet 1994; 344:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/26\">",
"      Singh BN, Kehoe R, Woosley RL, et al. Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: a double-blind, randomized parallel evaluation. Sotalol Multicenter Study Group. Am Heart J 1995; 129:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/27\">",
"      Roden DM. Usefulness of sotalol for life-threatening ventricular arrhythmias. Am J Cardiol 1993; 72:51A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/28\">",
"      Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med 1993; 329:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/29\">",
"      Haverkamp W, Martinez-Rubio A, Hief C, et al. Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. J Am Coll Cardiol 1997; 30:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/30\">",
"      A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997; 337:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/31\">",
"      Domanski MJ, Sakseena S, Epstein AE, et al. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators. J Am Coll Cardiol 1999; 34:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/32\">",
"      Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med 1999; 340:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/33\">",
"      Wichter T, Borggrefe M, Haverkamp W, et al. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation 1992; 86:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/34\">",
"      AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003; 42:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/35\">",
"      Ferreira E, Sunderji R, Gin K. Is oral sotalol effective in converting atrial fibrillation to sinus rhythm? Pharmacotherapy 1997; 17:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/36\">",
"      Crystal E, Connolly SJ, Sleik K, et al. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation 2002; 106:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/37\">",
"      Kerin NZ, Jacob S. The efficacy of sotalol in preventing postoperative atrial fibrillation: a meta-analysis. Am J Med 2011; 124:875.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/38\">",
"      Capucci A, Botto G, Molon G, et al. The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta-blockers to treat symptomatic atrial fibrillation in patients with brady-tachycardia syndrome implanted with an antitachycardia pacemaker. Am Heart J 2008; 156:373.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/39\">",
"      Oudijk MA, Michon MM, Kleinman CS, et al. Sotalol in the treatment of fetal dysrhythmias. Circulation 2000; 101:2721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/40\">",
"      Soyka LF, Wirtz C, Spangenberg RB. Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol 1990; 65:74A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/41\">",
"      Multicentre randomized trial of sotalol vs amiodarone for chronic malignant ventricular tachyarrhythmias. Amiodarone vs Sotalol Study Group. Eur Heart J 1989; 10:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/42\">",
"      Lehmann MH, Hardy S, Archibald D, et al. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 1996; 94:2535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/43\">",
"      Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270:2590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/44\">",
"      Zeltser D, Justo D, Halkin A, et al. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore) 2003; 82:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/45\">",
"      Locati EH, Zareba W, Moss AJ, et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation 1998; 97:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/46\">",
"      Drici MD, Cl&eacute;ment N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 2001; 24:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/47\">",
"      Kehoe RF, Zheutlin TA, Dunnington CS, et al. Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias. Am J Cardiol 1990; 65:58A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/48\">",
"      Gottlieb SS, Singh S, Munger M, et al. Hemodynamic effects of the class III antiarrhythmic drug, d-sotalol, in patients with congestive heart failure. Am J Cardiol 1996; 78:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/49\">",
"      Dorian P, Newman D, Berman N, et al. Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia. J Am Coll Cardiol 1993; 22:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/10/28841/abstract/50\">",
"      Lee SD, Newman D, Ham M, Dorian P. Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence. J Am Coll Cardiol 1997; 29:100.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 925 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.247-661AF214C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_10_28841=[""].join("\n");
var outline_f28_10_28841=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10900382\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ELECTROPHYSIOLOGY AND MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Class III activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - d-Sotalol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Beta blockade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Effects on the ECG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DOSING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hospitalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Oral sotalol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Changing from other antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Elderly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Intravenous sotalol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      QT interval prolongation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CLINICAL INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Atrial arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Fetal arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MAJOR SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Cardiac toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Proarrhythmia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Bradycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10900382\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/925\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/925|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?35/57/36766\" title=\"algorithm 1\">",
"      Algorithm for the maintenance of sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/925|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/55/16253\" title=\"figure 1\">",
"      Myocardial action potential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/17/23837\" title=\"figure 2\">",
"      Ibutilide sotalol AF flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/925|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/52/2892\" title=\"table 1\">",
"      Vaughan Williams classification of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/48/2830\" title=\"table 2\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/925|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/23/43380\" title=\"waveform 1\">",
"      ECG Torsades de pointes tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=related_link\">",
"      Diagnosis of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=related_link\">",
"      Pharmacologic therapy in survivors of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/53/16217?source=related_link\">",
"      Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=related_link\">",
"      Sotalol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=related_link\">",
"      Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7674?source=related_link\">",
"      Ventricular arrhythmias during pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_10_28842="Cutaneous changes of Stevens Johnson Syndrome";
var content_f28_10_28842=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F67632%7EEM%2F76141%7EEM%2F73805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F67632%7EEM%2F76141%7EEM%2F73805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneous changes of Stevens-Johnson Syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Generalized eruption of lesions that initially had a target-like appearance but then became confluent, brightly erythematous, and bullous. The patient had extensive mucous membrane involvement and tracheobronchitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. In: Color Atlas and Synopsis of Clinical Dermatology: Common and Serious Diseases, 3rd edition, Fitzpatrick TB, Johnson RA, Wolff K, et al (Eds), McGraw-Hill, New York 1997. Copyright &copy; 1997 McGraw-Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cutaneous findings of Stevens Johnson syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the vesicles and bulla that are characteristic of the cutaneous findings in Stevens Johnson syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Mucosal changes in Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Changes similar to those observed in SJS/TEN can be observed also in erythema multiforme majus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_10_28842=[""].join("\n");
var outline_f28_10_28842=null;
var title_f28_10_28843="Esoph CA site";
var content_f28_10_28843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Primary site of esophageal cancer based on proximal edge of tumor",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Anatomic name",
"      </td>",
"      <td class=\"subtitle1\">",
"       Esophageal location",
"      </td>",
"      <td class=\"subtitle1\">",
"       Anatomic boundaries",
"      </td>",
"      <td class=\"subtitle1\">",
"       Endoscopic distance from incisors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cervical",
"      </td>",
"      <td>",
"       Upper",
"      </td>",
"      <td>",
"       Hypopharynx to sternal notch",
"      </td>",
"      <td>",
"       15 to &lt;20 cm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Thoracic",
"      </td>",
"      <td>",
"       Upper",
"      </td>",
"      <td>",
"       Sternal notch to azygos vein",
"      </td>",
"      <td>",
"       20 to &lt;25 cm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Middle",
"      </td>",
"      <td>",
"       Lower border of azygos vein to inferior pulmonary vein",
"      </td>",
"      <td>",
"       25 to &lt;30 cm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lower",
"      </td>",
"      <td>",
"       Lower border of inferior pulmonary vein to esophagogastric junction",
"      </td>",
"      <td>",
"       30 to &lt;40 cm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Abdominal",
"      </td>",
"      <td>",
"       Lower",
"      </td>",
"      <td>",
"       Esophagogastric junction to 5 cm below esophagogastric junction",
"      </td>",
"      <td>",
"       40-45 cm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Esophagogastric junction/cardia",
"      </td>",
"      <td>",
"       Esophagogastric junction to 5 cm below esophagogastric junction",
"      </td>",
"      <td>",
"       40-45 cm",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_10_28843=[""].join("\n");
var outline_f28_10_28843=null;
var title_f28_10_28844="Pancreatic organ injury scale";
var content_f28_10_28844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pancreatic organ injury scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Grade*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Injury type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Injury description",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"       </td>",
"       <td class=\"subtitle1\">",
"        ICD-9",
"       </td>",
"       <td class=\"subtitle1\">",
"        AIS-85",
"       </td>",
"       <td class=\"subtitle1\">",
"        AIS-90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        I",
"       </td>",
"       <td>",
"        Hematoma",
"       </td>",
"       <td>",
"        Minor contusion without duct injury",
"       </td>",
"       <td rowspan=\"2\">",
"        863.81-863.84",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laceration",
"       </td>",
"       <td>",
"        Superficial laceration without duct injury",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        II",
"       </td>",
"       <td>",
"        Hematoma",
"       </td>",
"       <td>",
"        Major contusion without duct injury or tissue loss",
"       </td>",
"       <td rowspan=\"2\">",
"        863.81-863.84",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laceration",
"       </td>",
"       <td>",
"        Major laceration without duct injury or tissue loss",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        Laceration",
"       </td>",
"       <td>",
"        Distal transection or parenchymal injury with duct injury",
"       </td>",
"       <td>",
"        863.92-863.94",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        Laceration",
"       </td>",
"       <td>",
"        Proximal&Delta; transection or parenchymal injury involving ampulla",
"       </td>",
"       <td>",
"        863.91",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        V",
"       </td>",
"       <td>",
"        Laceration",
"       </td>",
"       <td>",
"        Massive disruption of pancreatic head",
"       </td>",
"       <td>",
"        863.91",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Advance one grade for multiple injuries to the same organ.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Based on most accurate assessment at autopsy, laparotomy, or radiologic study.",
"      <br>",
"       &Delta; Proximal pancreas is to the patients' right of the superior mesenteric vein.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore EE, Cogbill TH, Malangoni MA, et al. Organ injury scalin, II: Pancreas, duodenum, small bowel, colon, and rectum. J Trauma 1990; 30: 1427. Copyright &copy; 1990 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_10_28844=[""].join("\n");
var outline_f28_10_28844=null;
var title_f28_10_28845="Insulin secretion in NOD mouse";
var content_f28_10_28845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F53657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F53657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Recovery of insulin secretion in NOD mice",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 233px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Insulin release from isolated pancreatic islets from in 12 to 13 week-old nonobese diabetic (NOD) mice and normal mice on day 0 and day 7 in culture. Measurements were made at baseline during incubation with low glucose medium (B) and after incubation in high glucose medium (G). Insulin release from the islets from NOD mice in response to glucose was low on day 0 (second panel) but above normal by day 7 (fourth panel), suggesting the importance of in vivo inhibitory factors such as locally released cytokines.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Strandell E, Eizirik DL, Sandler S. Reversal of beta-cell suppression in vitro in pancreatic islets isolated from nonobese diabetic mice during the phase preceding insulin-dependent diabetes mellitus. J Clin Invest 1990; 85:1944.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_10_28845=[""].join("\n");
var outline_f28_10_28845=null;
var title_f28_10_28846="Superficial burn";
var content_f28_10_28846=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial burn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 272px; height: 319px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE/ARADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5WpM0VLBE88qxxjLMcAUDSuWNMsZL+5EcYOB94+leueGNFS1hQIg6Vi+ENGW3RQBuY8k4616dpFiFQcVzVJczO6lT5F5j7CwGBgVt2tlwDirFlarwMc1s29uAOhqUbGcloAelTra8ZxWutsDjI61OLQEcCqSJuYYtvUVDJZ5PA710ElqVHAqLySB0pjXcwhalT0p4gBxxWsYOCaiEYB5FAJ6lUQkqOOlNe3LdODWkqdxUvkgrnFCQ2YE1uSpDDIPauD8W+BINTVprRRHcY7dDXq8tuD1FQ/ZQD93FJx6BGTi7o+f9MvdV8Lz/AGTVIJpbMHAbunuPUe1ej6FqiXkSvbTLLGehU8j6jtXZ3Wi2t7EUuIFcH+8KyP8AhA9OjnM9oJbaU/xRMVrP2bT0OuOIT3WpoWN3tiwT+dacd2jAc1hPoN1bDEd/IVH/AD0UGtCw0t5SFmuCh9VXg1SvsROV1cvi92nAanPqKquC3FQT6DcRPlGaeMjK7eMkdj9a0F0e3WJXMTBiMlXOSParSZk5oynmmvG226Eg/wAXarNvpyQHfJiST1PQVe2GIbVAA7DFNZjxRYzbbGPIQMYxVO5kPTNWZc1SuEPeqVybGZelQpJPWuZviFZjXTzw569qxb+23A4FA0jF87A6VFJITk+tXPshA6VGbbggjmhBoZzElsD8alWEsACvWrH2fD8ir1tCBgY5osGhnjTlYcrzUcujhzytdLFEMdKnS3GORTsSz4/rpPCNgbmZpiPukBf6/wBK5zvXqHgm0CWkQZeQvf1PNOo7I5aEbyv2O18P2QSNeK7fTbYHAxxWLo0ACrxxXW6bEMDj8awOxFu1txkcdK17WD5c4qK1iGBmta2TA4FUkDFjtgwzipBb4HSrtuoK4xUvlgHGasi5nPECnSqz2+SdorYaMDgVW2fMQaBoynh2g561RljOcgcVtzxEEnH41n3EZ3DB71LZcVqQJGMDPSnx8HHanAYFLjIoGDrg55pERSM1NjcMU0REYI4p3CyFEORkVJGgzipIsnhu1SeSCQRwfanYcbdRPsySIQ3cVSFk0M3yA7e9aBiZCNpyKlSUBgrIRnviptfc1TaWmoyNnhXH8NOMquDxUkhRuP5VVEZBIBqjOya1IpQGHA+lVSuD0q9wOG/CoZEBOQetMixSOPSoZVDAnFXHjx1NMKgDnmnYRjzRZJrPuLcNnit2SPNVJo/anYDn5bfb2qtJDhs9K3ZosqeO9U5oeDxSsBjGPDHinxLzkVbeEg9KYkeDwOlMCe3GD71dj5B4qpEhxVqI4GKCT48sEEl3EhGQWGa9k8MQfKuRz1NeW+E7cXGrJu+6nJr2jQoQMds1lWepnh17tzsNKi4AArp7BDgdhWJpke0DjIxW/aEhgMfLULc6DYtI+BWtbj0FZtoOMg1r2ysFq0QyxEQO1TZ3cEUwDA+tSdRnjNUIjII6ioyRuwetTmqsoO7I7UmNK46WJdh9azLmPaM9K1I3EinnkVXnjBQ56VN9AW5kEc01RhqmuE2nIqq8m1/QUrmqTexZwBytPj6HtTYyMZzxU8ZBOM1QrAi5FTxkqMEVGpA5HQ1PHyfb3qkKxKgDDPXHrUoAAxj86SMAkjPNSYx1HNMVyvJGp/gB96ryxA/dYj0q64PpUBHy560ApMoyRSFvvA+9Gz1qztI596ic0WKbuV5UGeKgdQDU8gz1qPbk1QiuU5wOlRTxcVbwO1RSZNAmZskfHIqlNH/dFa0gGDxVdo+etAjIeMFuRURi+bgVqyQj0qMQ85H40CM8KRx+tTbccirghB5pDCM5FANnyp4BgLXTvjg/LXsmixAKOK8w8BWxSJGx975q9b0WP92BnmsJO8mFJWikdTpi5UCt21TABrF0/wCVB9etdBZqcZpIuxp2oHTvWtbHA5NZcIPHYmr8IIxVIlovbgfwp/Ue1RAjFSgcVQJaDDzTGyVOKlINQsQD1pMDNjmaLU5Iz0dQRV9l4we9ZV8dmr25HUqf6VsoC6DHXFQupTtdFGaAEED8Ky72DZhh3rVkYrIVJ5qtepuQc5oZtGLTMZmZZMZxxVyCccBs5qnID5nzZ4NSAYx6VKZ1OmmtTYjI25XnPapYnySCOazrZyDVyLDvyPxFaJnNKkX4WAABqyWGKoxhlz+lWUJK89a0TOZoeAMHimOmDilL45JpvmKe9O4WuV5Bjr39KhdMgGrMgAOFxg9aQgAUitiiRg9M0nUYxirUiDqtRlNvNCFIpygKKqOSTV6ZcnAqs6DvVAiswJJFJsAHIqwEOcUpHGKAZSdO9J5XGMdauBAcjHNKIhtGaCWUfLNBiPYVe2e1KEBH1oCx8x+DbfyrOEdiK9J0YfL0wK4fw3HtgQegFd/pYACnPTrXLfU0sdJpwIAGODXQWuMY/SsWwHABP0rat1wwx0qkI0rcggZFXojxVOLCgDrVuPOB6VSFYtxnqanBG0VXQcA5FTA8Y/WmMccYzVGduvHarMj7R71QvJPkJqWNIyJLnz9UjH/PNSD+ddPZ/dFcLpbGTWLx+wcAflXc2LDao7UoalVVZ2I7q2IuA6jINV7m3yucYIrewCnH4VDNCrIQRyatxBVnocddwES5x1qPyzkZrobq0AU8ZxWeYMjBHWs7HZGaaKcSsD9KvwDHJOKi8gpnnNSxKenWmhSs0aClfLBxyBUSyEuckgjoBUe4glSaj8zBz1PrV3MFTLJkIGDSg8DB5qhJMwJGRU8E6tgHqfSi4OFlckJJYZp4ODUUmQxPPtS7iKpMykSuBtzUY6kY4pYzzzzUuARxTTIZRkTnIqvKvIAFXZuDgVXdc1QIhjTk5FNZeoqx90dKbty2eKBEGw+lSKvy4xUoHODzinIuDkdKAZF5YJpwjGDgCpioIoKgDApiPm/QI8xgYrt9OXA5Ga5jRIx5ajH6V11imMHNchrubljnjtW3a5YdaxbPOea14TgA00Jo1I8ZHPNXYWHAJrOiJODjOKvwDJyPxqkJovxj5fWnknFQR5BwKlJB4zyaYISXkZBrOvP9W3pirzdMA9KoXRyhFSy0c1ohxd3JxyZTXZWLdM+lcTpZKaneR+kmfzrrLabbGB3xSg9B1lqbcbZPXgVKDnis+1k+X1q2jjHvWtzFj5EVlwRWdcw7WOBWiXyajlTch+lJ6l05WZlGPIwKWBRuqRkdCRipooSPmzzSOlvQq3KBGAX0qpID/wDqrXmXKZwCRWVN8knHagcHdEDqQPmqDlGzk1bPK5PeqkvAwRSC7LCTEkc//XqxuIOc1lKx3gDtWkmCOn1poyqxSLEZDDjinOpJ4NMj4HGKkjBIyTzVmRGwyuCaTbhTxUj4B5FAxjOetMRVccYojQ45qZwMikztHNUA1VGeKUjaOOaYG+c+lG75uaVyWh6HJpTmoxndkd6GcA0xdTwvRgPJUdwK6ez5UcVzmkjbtFdNaKByDXKao2bQdBmtOPIwKzbU5OM8VqRA5ycU0Jl2HI4B/CtG17H0rMi69ea0LckL6k00D1NCM5GcUq/KM0yPIUGpXHFUJETHA+tUbpvlOKsTMTVCd/lOTgCpZaOWL+R4hnGeHQNXRWkwbmuTvzv8RqQcgR8/nXQ2ZAAx1NZp6mlQ6G2c4q8jHGayoJAAB3Aq4kmT6AVqjnZoK2aVSxOO1VlcEZB4qdD0BNULYkZQTnFACgZzSEA8HnNNOAGNOw03sMkbIOT1rJulySc1aln28E9apSkOp/SpZ2Uo8uowKBHgnkepqvL65FS5JJ4qOQEHngYpA1qUXJWQMDWjbSgjDHtVCXgGo4yVxRew3FSVjoY8YGOal3BQRiqdkTsFW2zkH1q0cjWthG5GfWmjpTmIAFROTiqFYRsbs55oPIxTAPmJOcU6QhTxzxQD3Isc9OlBHANOD8cimSuOMCgOojOBUUknPJpHfnPWq0zYGRwRTuKx5Npi/KG4rpLM/LnvXOaccopHHtXQWmSO9cpojagPQ1pxcgY4rJgyQAa1rbsPSqTBouQ53AY4rQtu3HSqlttPXj0zV6HcDwM1SJLkZJHXFEjFT14p0acZPWmOCQTTEVJ5BzWVfSBkIY8Vo3SdxxXParIY4pDntUSZrFIwtwfXJSPuqoArpLQgY5rl9NVmdpGGS7ZrorLJHI5rJblz2NmJ8DNWYXzwec1Qjzgc1bhOOelaoyNGLCqAB0q4hGOTVCJ6sxtkdatGbRPu+aiQkqwHpTAaXtyaoa0Mic/MQetIpJ6U6/BEuQKhiYFMYqL6nfurkgUFu/Sq9zGSTg9DxiraDuaimPGQKDNmdIM8U0YLgcU+QkOcUyBS830pDRs2o+QHFWgdzDtUMCnbUxBHarObqEo+XmoGUBascMMA81HIoAqiSuxNMY8c1JIQFyOtQk5FMBr5I461C57U535IzmoJGGM0BYa7Fe9U7mTqafLJxjNZ17IcZz0pXHY8/wBK5XH5V0tqh2jJzmud0xNqgd8V0Npu29f1rnKRr23GB1rShzmsuDJxgVo24OcHn1ouFjRiOwc5NX7WdSMdCKoRZGARxRgq5ZSeTTuWopo6JMEZB61HKNi8HJrLhvDGMOT7VYjvo5jtyA3v3quYzdJogumbBIrndZwYHz1robogdBWBqp3RMPWokaUzOsYwI1x2rZhwFFZ9jD8gzWhGuMZ6UgZaib5etXITxVNCNvAoln8mPryelWmTa5ppOqHFWYZQfu1zdrM8j8nFbFocDgdKaYnGxpbz1z0qUOCcVTD546GpFYg1RAy6Quc9RVNVIPFaEhDKRjmqLAoSMmkzpovSw9CfSo5tqryOT2pXl8tPWq8zFvm70DZVfPJIqzpkQ5c9zUB5wpGSTWraIERV44oSM5ysrFuFcLUkmMUxMgU2TdkVZkkITx8vFQu/GDUsjgDGcmqbN+dO4NCTtwcVXZu1LK+Tj0qvJL2pgOLckd6hlbAJprPznPNQzSkLkUgKV3cBD7VRu5MpRqsisgEed2ao3TkRgZ5xUGjSVjnNOyFHfPeuhtRgfKa53TT8oYnj0rft3wBxzWTJRsW3GM1rW4yoNZFo5Zulads55DcAdKRVrmjGpdgB2q7BAMnfzVKOVYxu9Kcb4FeBzTRSUraDr6NAMA1mklW4PToauZMmSai2BTyMmhmqVhouWx8/TFZ1/JvBGKnuo5DGWHbsKz1ZypVj3qQaVrl60U7QKug8cDNQ2y8DjtVpEGOnWqsZCJwKhu034PpU5GTinsg6+lMWxSt4H8zK4xWvbERpjNQop9sVKpHGOtCQpO5OCS1TKxJ61XU5xUm7vnFWiGTlgFJzzVWRsmpk6VVmyGIoZrRHyLlOtVZCApIqVmAUDNVpVO7jkGhl7jrVcybjnita3AyO9UrZQFANaMCnPoKpHPN3ZZ2gioJiQDUrtgEe3BqjK5+tNhTQFx1A5x1qu2ck+tOBBWopTtHWhAytP1znpVORyDmrEpHJqkzqAcUABcnn86ikkJHAqNpADyagmlGzIOKQ7Fe6Vd2e4rKvm3E+lX7iQMOD1rLu2496BnP6Y5Kr7CuktSSATxXIaVLlADnn3rq7AgIOOtYDRs2hYHvV2KQ/xnpVO1YZwKuSoZFUJUmkNyyJ9/yk9KuW0XmHP86o2dk7ON9b9tEsajjP1pouUlHYdHarsyT+FNlRQMZAqwScA9qqzZIJbFWYOTZRuMbeTxnpWTOArDb61pXPTp0rOuiCQe2al7mkdjRthhR3zVyPAGDWfA+Fq0JCR05qibFhsdqROepqASZ45xTt2V4ouKxN0I5zT9/PIqKPpzzTxjPHFUSPH+zT4zzzTFyDUygN3xQiWTxt+tVLjiT61aA2gkVUkBaQ96bZdJakRfsKaFJPU9asiLI4/GnRxYmAPSkatpEkCEgZ7VaU7WA7io+AcA81IMZye1WjmYSuME5rPd/m6mrcpB4I/GqUq7Wx2pM0i0AcDOOtQTvx1+tNOd2M4FQyuAeKaYSWtyvNKckVUkkyMA8U65Y8kCqjvgEcUhJCSuA3HOKhkI25zSORyc9ahkkGMUrlWI5cBcVnXXQnPNWpm496pznCEmmQcbo0wKj1J4PrXX2EhI+grgtBkLBRnIrudNYEDFYFpHRWXJwBitmAE8elYlkyjj862rZwcYzSY7GtbZ2jbxV6Igrisu3Ynjmr0TMB7iqQnEllYr361VlbIxnNPkckksQCKryviMsOcU7gkVJQecmsq84OQehq3JeEvhlPNVL3BUleahmvK1uXICCvNW48YrOtSNoOavqeB71RBaAA5FKpBHSo0J25zUq4IzimiWOUAnk1IoUH+tR4GM1IrD0polkiqD71KiHOKjXqOakaUJ1xmqJSb2HSsF4wOaiiXLetNMgd8447U+FuwHNBvGNkW44gOppJMbjg81LGCV96gJbzyCKoz3uKi5APenHO3PamjCkdeaJDkEk4poze5BJLjqe9QSuCAcc4pSuSc1XdiO2aTLVuhFK3HbNV5MBcnqKlkIIzVad8rikVboVbhwcmqFwctmrFwwAqnKcnNK40rELNiojzzTjycGmOeuKEDZFJyazr9tqYrTIwuTWJqj8kZqiDgvC83mLGwPXrXoOmDCjtmvMPBcweFB1r1DSz8i9KwZSOksV+UcVs2ijJJrHtGPGO9bFtlgD2oGacWVHHFWA5I6EnvUFsMqAanZCvOeKYEDqeS3FMfKnGae7jvVeSXJ5NINSvcRox3Y5FZ91jy2GPpV2WQHv161n3Z+Q8mkWri2hBjHNaMRJPHasuzGIx71pRMMZFMguIR3p4aq6NnpUwI28iqQE+c9KUZHOKjj45FPIY8CmQSoSFJxVeR8ng5p7HCEdqiCkk56UM1pEsBJOD1rVto1CgnqapWsJU7m6VoRLz7elVFE1Z9ETD5UyB1qEDJJ71ZkwEGBTVxjgDFaW1Mb+6VZDggEGjAK/SpJFy2KZwDmmTfQqSrhie9VZjtTJq7OoLf1rOlyARSKRUlY4+tVHwcmppvvdaqucEgmoNEyKbknFVpAMnOasyJuAGaaY8dc4FFh3KBUg9KhkOKuyDtWddEjrQIhmkO3FYV8dzkZ4rTmkPIrKuj8rMaaJZ5X4BuB5YUnkGvXNKcELg/WvBfBt19n1QIxwr8fjXtuizBkX0xWdVWkTQlzQTO2tHAYGtuxYscZHPpXOWJ3DLGt23lEeP0qEa3N2AhcAEk1PLIoX7w57Vhfa2CnnHpUEly5JJY/SquLlNK5kUZIIrPlnGck4qs7yHjdmq0gkzkZNS2aJFtrhAMhgar3cyGMkEZNUnUkHioJEPORSuM1bJh5Y+lXF6isWyuAjCNzj0Nasbjgg0ybMvRscfSpo2yMGqSvg1PG2SCM0xWL0bA/Wp165NVo+vWrC9BmqRDHBc54yKdCmJcNT4j3A6U8YMoPTNUNNlmMcVYiBxVZM5xVmE44q0ZMdOxPAIFOC/JxTJOXAHSpXP93tVLccvhRWbg80gA6VI/JqInHH6UEdCCYbT1qhKQQcir9yQV7VnyHKkZoZS2Mu5B5xVJyM81o3HTvmqMgHQ1mzRDFIGcUkxHoTnpRuKgnPSmmQFMg9aAK02ATnisq+Yc1ozPk8msu4+cnigbKMuBWHrU4gtZXJ4Ck1uzLhcmuI8c3Xk6TdkHB2ED8eKpbkPueLwytDMsiHDKcivaPB2qJPaxyhuo6V4lXX+BtSME7QM3ynlcmqrxurnHhKlpOPc970+7yOOh/StiG5Jx9K4XRrvcB82fxrqbGXcVwRXIejY20lLDGfxNPjXfnP51XiwSAe3Wr8Q7HgelIoWNflyOcUFCy81ZUKF9zTSvJoGUJI+Pf3qq6HGSDWqY8jkVDJFleRxQBkSx+1SWNzskEcxOOitVh4hkjjiqs0Q6U0BsrgjParKZK8ViaddEHypDz/CT3rYiJJyOlUiGXYifyqzETjpzVOI88GrETE84/GqJLkbEDkVOgy2T07VUVumasxHjvVIktKBn61OqjBPeq6nse9ToBnmtEQxyDMn9fSlkYgkdxQh4J7CmPgnNUhPcQnJqM8ZpScGoXfBOTSHYhuBkYqrInGQe1WZWycCqshx0NIZQnDDtVN856VfmBJ61VlUg4UZHc1JRn3DYByDk9MVWyduW7VcuTmQD9Kpy8ZyOKTKRUuXwcCqjEYqa4qmzjn2pAxlzzGTXlfxSn2ab5YP+skA/r/SvT7h8Rk15z4w0K915kW1eCKGJyZHlfAHHH1rWC1MKztBnkVWtPlMNyjqcEEGqtOQ7WBrVq6sedTlyyTPY/Dl6HjVtwII4rudLnJC9q8g8KXeIwmeBXpGlXQKgZ6dK89qzPb8zuoJs4yQD61pQjcmc9RXO2Eu4KSeK27Z9wAVuKLDNKM4wOtWI8E5NVYsY65qePPUUAOO3GMVHKM5BHFTgCmSKSc4osMz5IgGxg4qnMm1j6VsTR8ZOapzR7hkCgDHlTncDz29q1NPuPNj29GHUVVki7HpVVXa3n8xeg6+9NCaOmjOG/CrcT4GM9azbaUTRqynII61cibgYqyS9GSxqzEfmH0qhE2OCauJ04NUiWXVIJqXNVVzgCp0B2nnmtEZNE2SExnFM3bgeTTT0AJ6VGW+bjpTCwE4J4zmo5Bz81OJqF2FIoZIV5xVQqT7Zqwyg8VG+APmFIaKcuQaglO0dOtW5iPwqlMeoHSgZSmQPICeqiqVycZU1dZhzjvWfOeeec0mCKVyOCBWbJwCa0JzwazZjj61IFO6k/dEk1DpGmpdL5rrnc2BnpTLx/lx61g6t48t9Ds1s7BPtF96DoprpoLW7OTE3asjw6iiiqOA6Dw3dlJ9nt19q9I0W6wQc147C7xShlJBHpXe6DqAeKMk4OOhrkrRs7nq4Wpzx5Xuj1rS7ncq4PWuispRkYNcBo10CRljx0966y0nyBisTpOqhfGMGrkLbjnsKxrSUFB/jWtFhun40wLnQZqQcio4xjin5OABQFyOQEnAxVaQbcj1q75bb8kfLioZEXOKAMq5XjFZ00YwQOK2poqz7iL5sDikPoQaZcG3m8puEfpnsa34ZQXKYPHeuXuU7+laujXomTy5SPNX9RVp3IZvR1diA4NZ8TggAVbibHU1aJZb3fpU0bgA561VVlPAPNKGwetWibFlicc5ppYhcE1E8nHXNMMm6mIkc8dagYgdabuO6kLDePakMUdODUcrDBBpWdc445qtMx+uKYEUjFgR2qjMSCcVPJJgdPxqnKzF+DxUlkUp556VRmPUip5zgnmqkz5OAaQinOT61m3JweKu3T9qzJ3zkimiWZt5uclYxlj0HrU/hD4cQWF4t3qP7++m/eHcOIwewqzor2sWqwy38ix28Z3MW9q09V8f6Yr3B01xc3kreXBF/I/Su3D0k1zSPNxTnJ8q2PlWkpa9P+Dfhay1t7u8vAsrwMEjiYZAJGdxFQk2YnBWdntAluVIXqqn+KteC5wwfbtx0NdR448NPY6pJLkvF1+lcbcHjA6YrnnrudtBpJOJ3miX4YRnPau40y6+VSPxrxrRrxkkHGNvX3FehaLehwOeDXM1ZnopqSuekWM2Rn0rahlxghhXHafc/IAvWt23n4HNIdjpI5MkMOc1cjKsvb8KxbWYBRg1pQSAtVCL4K7R6e9RyLkkgYoVhjbmpuq+9Mm5nyxZ61RliGSCK12Q9cZ5qnd7EGXxmpLWuxh3UaqpJ4rIeSSOYPFldp4xWxdK0znHTtVb7ISPmFTc05bLU1tH1JbtdrALMOo9fcVsoem6uLKm3kDxttZehrf0vUluk2txKo5Hr71rF3MGrG2PUdaTcQcGoY2NPLelWiLk5ckYFRM5HAphkwMY/GmFiXBp3BIkDkde9LuG7NRk5NNJIOAKACRlJzVd2O3AY0StgnLc1WMmeO3rSAiud2Dg4zVbcwU5OanmbnnpVGZ8EkdD2pDI5m55NZ80h9KnnlBrOuZgvWmhMguZOaoyE4p7OXamOwCk9cU0RJnG+Njd3MkFlpyM8rckDt9a6v4W+BrewYX+pAT3I6EjgH2q1aWaPIgRAZ5Opx0Fd/Y23kRxRqMAKK7qMb2vsebiJ30Pimug8IeJLnw1qyXdqSyH5ZY88Ov+NYRRu4I/Cm9KzTtqiNUe9w+INK8UWreTLumYYMDDDg+w7/WuF8VeHZtJxNIuEc8DOdv1rE8EeJ28L6o9yLOG6EibG38Mo/2T2rofG/jq01XTha6fC7PKv7yWUY2ewHr70pQUlcunNxemxyNlKztI4PyhsD6V1mgXxVQpbgHiuUsUK2a4H3ua09HP73y2PIORXNUjfY76E2lqer6XeAqPm5x0rprG43Ae1eaaVdPFKqP17H1rr9OvMnrxiuax2HbWs21QRWrazY/KuX0643DBOa14JgEwDnJpiZ0EMoPU81ciJPFYVtKdwOa04ZvkJ71VyWSXkuwbU5JrOkieQjcSatD95Luxkmraw7B1ANS9TZNRRnR2qqMsDmoLlQBxxWo4bGMfnVO6jDcUEt3ZhXEWQc1QO+KQSREhl5BFbk8R29hWbMg5x3oQWNnR9QW7iIJ2yr95a0g/Hv61w58y1mEsJw68/Wum0zUEvrYMvDrw6+hrWLuYyjZmiWwOabvycDiopH4wTTDJg9DVCLIJHNNklxmod528HmoZX45PSgBsz5Oec1A0m0eppsj7hVWV8cUrjCac81Qll9TT5nIBqhKxAPNADbiYDoc1mXMpZuKmuZB0FVRy2T2pktjgMLzVe4dVIDHCk4NWZCFWr+g6Qbm7W6vAEgi5QN0J9TVwi5OyMas1CN2bfhnTdqGd1+ZgAM9hXVRwhYo3YgBeCazhfWttAWiYN/Ksi61OSZ+ScdlFerGKgtTyXeTueA/2ZG3VAfwqGfRIWBxEufpXQRIDyKnSFSCcV4F2j3ml1Rw1x4cU8xEqT71Vs/D++8WO7ufJhPVwhY/lXoLWwIyBiq8tmrfeAxWkaskYyoU5dDH0DTIH8WWumwSedbhv9Yw6gCr/AIi8NzaXeefAA8BbKsvarFjaG3v0kiYRsVK+YByAeDXs/hrTNKv9CjsPLLRsvySMPm3e9dEF7VaHPWvRd1qjx2wVZotrdGHB9DV+0le0lEUuevB7EVua14c/sa+eMf6lmxgH7prOuYAWNvOOB91h2rGcDejXXTY3dNuec5wK3rW4BAANcJazvbuFkOeOCK6LT7nK88Vide+p1ttMccVft7gs2AePrXNWsxwBuOa1LWQKwPPNA1Y6OGZF7c1NG5Ylz/8AqrFhm+b19KvwykR9e/NMku7wWyTiq8wLngc96UYK8mnMQEGBkniiw0UJUHTGapTW5A9q2THkE55qmwLMR6UWHcxnhDA561n7pLOcTQE5HUdiK6R4RjjGaz57ZcHNGwnqXrW7S7gEsZ9ip6g1Jv55rmvNawufMiPy5+Zf7wrbtriO6hEkJJU9iMYrRO5DjYsSSAD7wFVppe3akkTnPeonH40xKwx3xzVeSTcKlkBNVpVx0oArysT7YqhcvmrVwcLgVnTNjigRBJgtyabnjgVGzln2jvW7pGnpHGt1cAOM4RfU+/tVxi5OyMpzUVdlez047RcXnyxDkKerVlXWsNf6+bJGZUtwSyjgH2p3jbUb9dY0i2iKLDcTDzR39qsajDBB4tVkQBnt8yYH3sGu+FNU1ZHnVark7s0YpGdAoPbj2q7YbN4ZuQO/qawVuirPEmdznAPoK3rFVjVA3JxVNkJH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Red burns that blanch are typical of superficial burns.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Morgan and William F Miser, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_10_28846=[""].join("\n");
var outline_f28_10_28846=null;
var title_f28_10_28847="Oslers nodes in infective endocarditis";
var content_f28_10_28847=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osler's nodes in infective endocarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 247px; height: 283px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEbAPcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDTZhuI2gjtnpSu24c5P+1/F9Pelm3cscEdRxg/5xSSAruUjAxz9K+RPpGis8GRlirD1Xg9e9Vxxyp+U9fbtVxxvXGM47g/59KaEXoTgg5BB61Vx7FXyjkgnI/pVcRBc5xjv7VamGAMECs658wIWQ8n161cWZyZUuJlhDZI9Dn1rPt7xWmIDDr0rL8RSXZgkFucPngkfnXN2l5eW5/fRvnPPy5rsp0eaN7nNKdmeoQXpjAxnJ5Fblnex7IgMsqscZ9e/wCNeWWuuSKQzDgjutbVlrqtKGJBI7ZrKdBopTXU9HknVm+XAOMAg9KepVSNzAHnIH+eK5S21+OQjJIb6VqQXayRsFdeB9eawlBo0TNcPgZUnHU59f8AOakjdnhVQU477azbOflVYDAOCK0UkVEztC5OeT9azaK5h6wu24Hyyc/wnGKqzxqxI3deSCP89qma8Qvtcqe/QA0kzLhRwD29B/ntSSYFCSMLllY8dzyKzrltpODwOhFbEkSsg+YFj2/pWXdQ7JFDDkkHPqDWkQuN3AbQBvy3GRzwKlYK4fZDwCFyvFLDIsbMxzkHrTYGVhlyF5LFgORTuBWliBmjY8AZJ56kCqXlL06cDg49M1rHGHOcEADnnr9azfmMmcgA5+tUpAkQ/ZsS4ZRtOehzTmt/lz2x0FXwq4wwwfQDikSPAPOQOlHMKxjyWoI+UZ55qM2mVIHXsDWzJbY5Uk9zkVX2lhg4J9KpSFymPLYZySMVTl08c5UfTFdUITkA8Z96iuYkaM8DePpVKbJ5Dh73S43GHjRh64rAvfD8ZyYCYz6dRXoMsGRgr164rNmtQTkDI610U68o7MznSUtzzeTTblGP7sMBxwaK782a4GRyeaK6ljX1RzvCxPVkAIGwdR0Hf/P+PrT4l862Tch6dcenGD+lVrdyspJO7jrkYq4jgQJnIIyD279a8Fo9R6DRa4BwMZHY88ZqK4jCH1Q+g/z6VZaRChK4zyCOnrVbduIJHB5YDvQJFKZAqt8w64rMmAbAD8dOe/rW4dznIB4yeVz+NZcsTkck8A+wrSLJepg3dirFsfniqa6aoJPH19a6Qxb0wfvE8+3FPhsMk4I/XNbc9iOQ5k6cvfB9arzaTGx4VQexxiuv+yFjggEHv1/lUUliDxsI+h/xpqqS6Zxp0+5gJMTnn1FSRX9za8TKdvcjpXU/2e2OhCH8B+tQXemcfKu8fnVqqnuQ4W2K2n6+pQEkFM88ZrcttWWUoVO72zyK4670oK5ZNyN1JHf61S+0XVix80EoON6dB9RVezjLYhuSPRmvFJDMMj3OcCnx3AweSFPZTnn1rgrXW0Kr86sB6HrWrDqkLKuyVQSPuk1DpNFqpodkJVz82COPbHFVdRczdcLjkdPTn8K55dUI4BQ9+DT11qAlPPfaw68Z61Ps2PmRoFQ7ABmVyxbDf3ew+pqWSJhO6+Z8qrlsj5cAUyK4hmCSRSI7Hn7wJHYCrKfPFIBgqQF9ev8AXik9N0O/ZlL5vKXex3yNuwTyB2q1BAETP8XQAf5/ziprqKITpgKoVFGRxzxUsaGRMY9Sc96hlpkDRqWyMjI6mpUiJUDO0g+meBU0aBXU4GAKsRKjMB0AAHBxUNlXKzwZUFcEKBz0qE2ZiJIG5j8zZGQD6VpRgBQjjfHncW6fhmopFYv84HJztJpJjRmyW8iIjlVw3OAeaz7pSdxBwx5OR1rpZpA6Ijg5UfK3r19/aqFxa55AG31HT8qpSCxzjIeVYfXNR/Zt8LSf3jgfStG6gK7iMDjIqNP3aIvynYM8VopBylJreNcqOOxz3NFPl2nrwfUDrRT1E4o6fYvPXZyOBzU0bExbc4CE8g+vNWdoWIgqOfaoYjGEw+MAkkgc/wCe341z7jciNHKttkBwvTt36UPKGbJcYPT61OzI0e95MOeTk5A6c1DGIpm2R+YQBgHg89hRbqJMRwqj5GL5XBJ71E0DugIYfMexzxVxbIttCbs7TuDHgnNPRCMsNoIOF3c/U5ovYe5Xt7RQckqxzu4PSrD2wI2gEZGTjH8x/nip44wAuMFiOBU8EAbKnjJwARyB/Koci1EyzbFXXOVBAPNTfZPl+UNgc8cj8q1pIQpcvyQOxxn/ADikVCQT0A7Y4P8An1pcwWuYkkIUfdCEeowCPp2qlJCA4JBU9mHI4ro5IS0eSoC9cjv6CqcsCAFWGDn+HuPp9aamS0c7cWys2WAx69qyL3TgynAHGT1rpbqIg4Ug8YxiolgPzbSMfTNbxqNGcoHmuqaIHdjDmGfHDL0/EViSWuqWzE7fMUHgo3P616xd2QcjcF3Hv6VnTWOAMqCM88c11wxOlmYOlqebjUZ4yRKskZ/2gQP8KnTUg5wXJH9a7SXTY23YRTj1GKz5fD0Mx5t4y3c7ea0VaD3RPI0ZNnqggbPOM9M10Gn6+DtBkwOvrWDe+GnjJNtI0f8AssNw/wAayZrO/tAS0O9euYzn9KrkhPZibaPSf7aWRcq24k5ODV+2vd0SYP15/OvI4tVaJlBYq2f4uDWvaa864+fntWU8M0Uqh6p9pEgLf3eKkR88EYJHPeuD0/xACVE0hH0PvXR2uswOAPMBwO46VzyptF85umZlDHOSf5U1Z/MdeeQMH6/41my3kMi/JIGGe3BFMW4QqG3HnpnIzWfKaRkb4CscdQf4f8/h+VTwhDlcAAjg4x0H+fzrn1uSCPnyMcnOasG63xDD845FHKO7G6jCHUMv8benFVEsAzyFi2cjpx+H545+tOuLlvMh3HKrzn2z/wDr/OrGn3SsjBwoPUkjqT7ew4/GqtpoNSsQGzTkMufXtn6f56Y9aK0meIjcNu3OCHOOff8ATnuT7UVN2XoQanq0dqrAsMnoO9YA1HUrksLWGOKMnAL5yRWBp1w00hmnkLsTnJ7/AErqNOkiYDn5R2rf2aprucnPzMZFFeYLXDxyL06ED8cGtbTt2/aSIn6lckZ/+vViBlRVIVOeOvH0pJ7dUO7LJjuen51jJ30NIs1YPNQKr/N0HJqRoncAR8cc5OR+VZUF3JFIucE+tadrqKKhXaV7A84rGUWjSMh9vEYx8ynd0+h/GtK3RVXqoAGQOuappNHIxO44JHy/5/CrsLowU9OpznpWbuaKQ6TJRydrN90ZGPxpAm3G4OoHqOlSMUf7vzH3Ocmnqpzgtz25P86kvmRRn+XgMMdRxjPtUMgBi3FRwOnf/P5VovEijJXKE4z1/T3qvJGTHjglsYGe1NEtnPSqytuJXBHU/wCNORUMaITh2G4lhx7YxVqSFZenysBiqN1aMrlsYBUewrRC3JAiTLgYIDYDA56D25pk1ijlM4ySScHHH41DtdBlQOBjpTTPKAS6qQRtHoB61WpNip9gJbcFzig2qxtwME88jHFTpIxG0EZPb0pjIxIwSC3ctjNUpMlxKF3CFADbTk8e/wDnms+WxViSQMHuDXQJaSEYjO/P91v6U17Rhjei5/3f61anYhwOPvdEhnG2SNW4/iAJrnrrwlEDmCWeH2ByPyNeoC0ZFxsIz3BB/Q1BPbxk/OF9MjI/lmtoYiUdmZunfc8eutE1W1z5LpMg6fwsP6VVGoanZEiWJ1P+0K9fl07euVVSvqrD/wDXWTe6SpUgqp+tdMMYnpUjcxlQf2XY8/t/FVxGfnHX3rUt/GCj7/HrUupaBG+dqbT1yBxWBceHrkZ2Ro3oQ2M/ga64xw1VXTt6mLdaD1VzsbbxNDLgCQEem6tKHWQ4ADDHbnpXlU2mXUDHzYWT/aI4/Olie8gwY5HGPfNJ5epK8GH1rldpI9ZbUlbBzg9AKdHfbDlSF7ZrzCDXL2Hhwsn14q9B4mQ8TRup9RzXPLBVI9DaOJi+p6bFqCsAAQB7UVw9p4gtnJ2yjPo3FFYOhJPY6I1rrQka11DT3ICG4jB42HDAfTv+H5Vb03WkY43BWB5Q/Kw/A812k+nAhjtww6qeRWLqehw3QxNErntuHI/HrTjXjLSaMZUWtYl2w1b5euRxW7bXySJjdz0FeaTaXd2DZs5Dt/55zcj8G61La6tNbMPtkTQj+/1T8x/WtXg+ePPT1Rj9Y5Hyz0Z6cVDqwU5HXBGabGzR9Qdtc5pusKyowkDL6g1vJdxTKCxzj0xzXFOlKO50xqpl23k/eBlJbB7jpVyOZk4OPm7g4/Os3tuTJ/iHuKnS7AyrKrDpkDH4Vi4XNVM0luGDZwQRx1ztrRtLzCtucFx0rn1nRmyCOR19qSRtuWxjp7/THpUumXzpnUrIJVyuDkFcEdOPy5Jp6xoXwu3jPUY56Zrn7a/2NheMEHnqvoa2F1CJgVJORznA6/WpcWhOdypewBXcKxbAAB6EmoxbOzEMGIVdxDcZPQDNXZZ4WlOyZXbIAxxx1P5CoHmlMQZQNrkvnOPbn8DRew1qZc8EqxyMFIC4VSRzuP8A9b8hVaSzlcYwNqjHtx1xW/EhmFurA7UBfafU8g/lVtbbamCDkcAk9fcUuexdjlorPc2Gbdke9W/sRU/dI46AVuxWauuV4xnj2HFWFt1D7iwU9CMdalzHoc/HaPGC20lc554z7USqGCjYQcYGcn610ki4jcuUPUYUEEiqgtgGZ8ZwP0/ke35UcxNurMQxkjjJAPU44Hpng1BdwAxDv6//AFuK3Ps+NzLlB6f0xWfNG2GVI8cYG044/wA+1VzBypswzF5bAlQRjGcdvwqhfwZI2g8DmtlscBjnsO/4VEUDMA+CfRu+KtSK5Dlri3zwy8nk8UxNPRwMryTnnvXSyWaTmR0GCSAM96iFp5RwpBA9a15zNwuzmLjS0KnCkmudvtChfLKhRickrxXorKiqeOM9/wDP+c1SltldGOOevStaeIlB3i7EyoRmrSR5Zc6E4TamGx03DFZbaRMoIZCrA/UH8a9RmteflXC44zVSSyJ4KkmvQhmM18WpyTwMfs6Hl01jLGSSucegor0WfS0c/Mv5iiuhY+m94nO8HNdT06K2Pyg4x6Y6/T/D9KgntllyqqBt454z/j9PyrpVshCBxtDcjnK9Pbof5VRvtPOSwAG4Zz1B+nr2r5pT1PZlFNnI3tlHIu11BIyAT/I+lYd1YtF8yDI6Ee1dTe20qSEOScdTn/OazbgFRlfmHHuTXbh8ROlLmgzmrUI1FyyRy39nW7OXRfKkPVoyVz+VODajaHdbzpMB1WVdp/Mf4VpXUWHLBcAHkUyPDAMDuB719JQq0cZH3lqeFWpVMNLR6DLXxHPHj7VbTRkfxqu5fzFbdlr1rcjAmUN3GcGspECvwPvVM1lbTcyxI/vt5qamV0pfC7Chjpx31OiiuEkIwVycHCkGpW3AHhgD1rkBpiQtmxuZrV/9lsj8jVmDUNZtxhnt7uP0YbW/PpXDUympHWLudUMfF76HRISpLYYAdDkGpC2Ty4wv97gj/Gua/wCEhMbf6XY3EQ/vKA6/pV211O1uVzHKGJ7A9PqOorgqYSrT+KJ208TCWzNWKTY4bcFyOcdjW1a3Yki2k9Bjr71zsc0bYO7PGOtW7YEg+XgkjGK5ZQfU6VOLOst7lT8zZJ9h+FX1kX+ADp19/SuSt7mSNgMHGecGtKG73rhcc9SDya53BlpnRQ7FQn72fXoPqKQ5ZiSAoAwe9U4LkSADcc9gRkUpnC54PzdTms2tRq5amUfIuO+CoFMUu28kEY6nPWqwmBU5Oc9ST0H4U6KbAAJHI5z7eooSKd7DpWBiO1NxHVVPPqfwqhcQbxnB39MbRwPqDWqESTaHwwycZ745P0yaZcQPyEKuqdM8nr6/hVIS0Zyl3ERI3DZH+etVFLljzwxwOM1072g6HPJxz1H+cH9Kp3Fl5TjAyF5OBnFVc6FJGaItjZjXAVSRg9agkXdjIBY9SfWtSKEsuRnJPbr/AJ6VUuIyG5G7bnvxQmStysIEdR5i/MxwCP1qtNZEtlc8+g6/hVti7Ow+Ysgwx6ZPep4gzxklseu7j+f1/n3qrtFWOfmtWj5I47EmqkkflvgYw3bNdYbNXUgkEYz3waqT6WGH38egPc1aqCcTnJY+NrLgCitf+yX2Mu9TjsaK0VRdzJwR6IedzRsBjhs8gnt/n+VVLiSONkaaONiCTHuAYrkYLD0+o57citCeNQsjqRmI4YsRhBjJHOefYfj6Vy19cySEu7H97/exyv8Anv7VyKLFdMNRWOdiqHfGnRgMEk+w/SuZvrOWHdJtyBxg8nFbTTLj5gEC9DyD/wDrrPu7grlckrn72MscdAe2M81tBtaEvU56c7xhgVxwVIrPdJIm3R/Xbxj8a3pSsuSVAP06f/XqkbYEHHX06V1U6rg7x0ZjOkpq0jOFwDxICh/MH8av2z7o8r0Pp0xUUluOOxPbFQrbSQtmBipzkqejfhXr0M0a0qq55lbLk9abNMID9AKFi3Y2gtVS2uvm8uceU3Yk/KT6VrjYgJyf6/8A1q9mlWjVXNB3PKqU5UnyyVit9n56fWopdMs5yDLCA/PzLwfzq48ygZHXFRfaVJJPNaXTM9SkNMli/wCPW7fAH3ZPmH50Ld31k2Z4HeMfxJzj8KsS3mAQg+lQieRjyCPxrnq4OjV3ibwxFWGzL9t4ktJSqyzbJT2fgj8617W8jkHyTIR2INctJbRXCkSxKwPqKp/2SkUhNrPLD7K3FefVyaL1gzrp5lJfEjvYr0RtkPj0waufbmdTkq4P+1z+R/OvOgdThbEc0c2P73Bq2mp3tvxPbSgdCU+YV59TKKsdlc7YZjTluzvI70M2GwCOxOc1OZtw+Un1561wUGvR7zlwmf4WG3+da1tqyMud42n8hXDUwc4bo7IYqMtmdZBfGMLxg9B7d/54q0L5QmQ/JHPeuWj1SNjtyGxx1qU3UZ+7kHHb+tc7otGqqpm99qJbOd2TnPrjFMkuS8zFgdoGAvTIFYsV3hxtOMH1qdrkPggjkY5oUGhuSZqxqhQcjcwOQOCPY/59aBCjIChG0Zxn1z/j/ICs9LgZOWIbHXOD+dSrMcICwx2+tS4suMiwbFIoVYnByW56D8P8/wBarmDMeMYBJY8ev+RT1uGkOyRht/iOM1MJcxdiC3HqB2qdTeMikIyEJJGDzx3HYVI4DLzgY688n8PSrGBhQVTJ6f8A1qjktBIDjgdc+2fekWzEn3LMdjnYR6ZB/nRVqW2wwILYUccUVopFaHZ6zLbvbw28YVFYk5j5+XOOT3ycnn0Fc5dCGacttBBAVSV4Cjio2vRuOFXcflB746f0qeICXadmAfbnp0pO8Tz4ruUZ4IpdztGUC9E9D/jVR7NTkgDd3ropLcIdiZIBwAPXvUYsEZh5RJH86XOaKJzM9hggIAB09qa9gyrkK3PAI6fjXWLaoh5AB6EY4qtLFHFu6k8jIAyT/kUe0Hy32OVNqd33Oe5x+tK9vGARImAR1xjFdIsSyBSUz1wen402WxDoWXGOmO9UqhLgcZcWKyFsICp6jv8A/qqhLb3EGfKlJUfwMc8f0/CuzltVCnbkEH15FZ13EMfdwc9R1J/Dit6WJlTd4OxnOhGorSVzlfPcnY+UY9FPf/GpQhP8Rq3qFujqVKDnt6+9ZLXElqdhHmp1APUfQ/4172GzRS0q/eeRiMtlHWn9xfVVHHX0FOwc+/biobe5jmXKHnuD1H4VMeuK9eElJc0djypRcXZijI59qc74Und7DNJ0B49qFAkI9qtMmxZsIouC5yevJrTVUK4A7c+1ZB+TkZyO/Sr9pOrqM9enNWmZyQ6ewhm5aFGz/eUGqUui2oUsqbD6oStaSttyBwevHeiZxgbs57Zp2T3EnJHPtpsyP+4vZlxz83zD9avJbaomArwy/VSM1q2luHcEjNb0dpCkGWI475rCeGoy3ijRYmpDZnGtdX1txNZy49YyGFOi1yHcPO3xnuGTFdBciFiURtx9hWXdqFDJJEpI/vCuSplVCW2h0wzGqt9SNL2NxmJ0ZcdM1aguGJwrc9OvFcvPpEc07SRl4n7GNsUtquoRhhFciTafuyDn9K4KuUTXwO53U8yX2js0uQH/AHjE49+9TyXCbCI3xmuHbxDJAxjvrd49vG5eQavWus21xkxTRM3oG5H4V5lXA1Kb95HpUsbCezOqtLl5GO4gDtzwavx3Plna439+R+lcxDdqzfK204q0t4QSCDgfjXLKidarpnQOzSDGOPp0orMtb0AgrjkdKKz5DRVH0NJoYJMMOGPHB5qZZPIVNo3Huaybe53YIPB9Ku7/ADABu5xkHFbTg09TjhNMvrdRbTwdv3Rx2qS1c7iQV74/z6iqKoSAATnp0zxU6xGN8YOB1Ge1c8onRFo0HK+UBjg8nHPHYfSqssCsrKOQfU9Pap45vMOcfMeeB0/z0oRAWVhnjn2/+vWLRpEpC2aP5cc9OO1LHEPusSM/xYrWhty205Bz0FLLbEEsw5Hvnj/D9KVytzBuITkgjIPXPf3rJvotoOB1HFdbeW2YyVjIGdxxj/8AV+PT61y+rHHyKOTwSCT+ZNaRBI5e8XcSq4yDyc8CsyW2U5XAJPBPWukngRBtVcNjnvtrMnhAbn8K6YyBxuc/LZhSCvGO4pqvcQD5HJH91ua1Wjzxxt9qglh+XOMn0rpp1pwd4uxz1MPGeklcZFqKMu2ZTGf7w+Yf/Wq3burJuQqy56jkVmyRdSBkGoVV423RMUPqDivTo5pNaVFc8utlcXrTdjdMmQdwyOxNOhYxyjBwpPc1jxajIpxOgYD+JeD+VXoJo5kDxOGHqDyPrXr0cTTrfAzya2GqUfjRsiZQMkgGovM8yQHPyj171TZjxyR+NWrMRKcyHPsa6EzmasbOnD7pX7ueTVi7uVYbEOB7etY8+oHbsiXA9qiidmIL88U7kcppJI8a5t5AjdPu5qrcx3Fw4e4ZXyMDjGKtwgMARyDzjpVgLknAIx1x/KqJvYzfIAAyBx2rNvInhlE0JGe49RW5OpT5jwPX2qlOEdGwy5PvQUmYzEXKktECCO/NVH0W2ky3lYPXIOK08BSQMYPXFTRqMdAeaVk9y722MH+zbqH/AI8ruRf9l+akWfVYR+8iEwHUocH8q22j6npn3pxjwpJx9PWsJ4OlU3RrDFVIbMx4vEKQsRcLJGe+5T/TNFTSRCafDDd9eaK43lNJu6bOtZlVStoOhnutLk24aSIHGCeR+ddHperRXKq0bru/iHcfUVb1LSEmG6JSMckda5C/01oJxJGGSReQw4IrTEYCFXVaMww+NlA9AtrhXJyQDj860N4ZSABnOOeMivObHWrm3YLdfvFzw6D5h9R3/Cuo07VknUGORJBnqP8ACvAxGAqUtWtD2KOMjM3LVGjfDA5zzk81owN82wjdk8kdv/1e9ULa6Dw44JHqP5dxU0Mgceqg8Z56150qR3xrXNe2nhySB8nABx09D9auSqk6rt6f3cDIP+fw/AVlqgVV7s55/wAD/iKfJNtj2k53dQRkYz/n69653Gx0Rd9UMv7sJZu7sDGo3ITnL54GPYnv1PXgcVzF0gW2MzkeY5wox1PrV7Vrxri4BkyLWPlVzku+PvH+QrJkkaWUOwO5vlC/3B6D601Gx0RSsUmQMDkknuT/AJ61j3yFd20cZwSK35YtobaDn19P8+tUWt2IIIXcB6fdFaxZXKYUnyk5AGOw6fSoSrdhntV27hdWzjnnAx0o89LVDHPEWz6DvW19DGd4mXNkfwn2yKj2Bl5ODV1WmubhY3jCFuOOMfWtptGhht1LMTKexOTQ5W0JWu5yMkDdSM+9VpLdlYMmVcdCDyK642S527SOO4rPu7Lb0GAParjU1JnRujGh1GWJwt2MjtIB/Mf4VuWwDxCQFSnYqeDWRd2p5JUZB9cVUjeazbMOdhOWiY/K3+B969jC5i4+7V1XfqeJisuvrT0fY6iNgzbfer0SHG7H5VQ0a4tbyPMO4Mv342PzL9fUe9bSlVwQAMdu1e7CSmk4u6PCmnB8rWo6D5cD8MVq20Xmck8eorMgAYnJGfrW7Zkpt+YDI/D/AD+VW2YSHxWCOpDjcMd+MVQu/D8ExzkqSO3WtCS7Eahz+nf/AD/Ss6fULhwFRjx0zzRqJXKEvh2CPazSds5J7/8A66qi0jhwEyR2rSEDtzISRx3qOVQM/LmqSK5mZzoOhAqG5KrAd3AA71eJQnGOaoaiQFCr35zTKRVsk3yMzDqe3eip4x5dvu6E9z2ooHa56AYeRkcnHt25ye3f9fSqF7p8FwCrDBHfH+fyrYmCgsq4U5Hv19fX/wDX61X2HcM7m+v+f88VCOe9jjbvQXV9oAbIyp/z7VjvYy27h4WMcg6MOpr014lEinDAdCD/AFH55H4VSl0mOcFlCg56Z60WT3NI1WjirbXJYMLdxsQDjfGP6Vv2GpRSoHil3IO6nj/PNVb3RJA5zHkE8kjgVg3FhNZyh4i8Ug67OMH0P/168+vltOprHRno0MfKOj1PRre9DKFyMAD8KluJd5JDDkYNed2etXNuQlzGSvd1H8x/hW3baxFOD+8APvww9q8HEZdUpu9tD2cPjoS6l68bcduCVU8L1qvIShBfPIyp7Y9f6UkkwKAD7oz0puDJ1OVByK4JU7bnr06qlqTBie/I/lUB/wBZjnHXOOcUjzqg2ZyenB5pEYE53c1ny2OlTQySASScYzx9OP6UXsEM6EBQr5BY9c//AK/epnk2rgcE+hqFZFRdxI25ppETsx8Fpt6qc9gMn+VLNEiLwrEDnHB/nmpRcqcKOd3I6H+lWrW0R7iORssyn5ExkE+pwfuj9abuSmjNFtlcgMB2yuP6VUuLYk4K8eo713GnabHIihEDAd8AZ/IA+/WmappBjXcoIYZ9/wA+tQ3ZmqknoefPp/mpyB7fWsyfTmVmzz9O1du1pgnjn0/z/wDXqpPahs4z064/z/n6041WiZ0kzgZbSW3mWe2bZMn3SP5fStvT9SW9UqQY5UHzoT+oPpVy8tM9Rwc81z11byQyiaAlZU5BH+ec969XA490ZWfwnjY7AKsrrc7awAVgXGSRggVea5SBR15429j9a5rTb0XNukygI33WUn7p7j/CriuZnwpznqBX1UWppNbM+TnBxbUuhe8wzsRjn+VXraDZhiAW4IB9P8/yp2lWQVleUFcjgE4xWhfRrEFlkbCcEknBJ7++cn9asybIMbm+UZwePU5/zmop7VDkNxg4IHanSXaNIrwtlx34x+X1qle36MWC/dPIAPSgCvdiCIZySR1wKwLmTzJcjp2xV25m81t2SPTJ61Utk3Tknt69hVGsVYsJGTGc53GipiAMqOo/zmiiwrnoMiBWHHq2O31BPbp/47TYlAPUBsDPYDPT8P8A69W3jfPyn5ewOOvr/wDX9+TxT0iZVGQcZ6kZx/n6fQVlcwKVzHuC4JJ6jHX8vUfzpkYO3IwcDsOPx/z6VqPFGAfNOOvGeT6Z/Hj175FZ91InzeTk5wMjg00xCpGGYY+7nksM8d/oaxdZ0+N2YJx+A5/w/wDr1sRyFRkEjBPT/P4Vns7SXJyfzqluCbRytzpTJlvLxxnrisfULcRr0I4xnofp/nvXqBiikh2yYIA/I+2O9c7rGjROWaIZA6LnP+fSh6msKnc4CHVrmzmIlUywemfmH09fpW/Y6lFcJviYMvfHB/EdqqahpygnMY46g1hPbvDJ5kTPG44yODXnYrL4VdVoz1sLjpU9N0dTcykLvXOwnkA4zUVncMdwPBHTnOaybLViXEdziKQHh+in/CtBZdrl1644x1rwa2ElSdpI9+jjI1FeLNDzA49QB1oK7o3X5uSORknr+Of/AK9Uftp3FmijkO7njqPbsKnEhIBRmOOhI5rm5LHR7Xm0K1pctFceW52sh2Elj0FdLp2tJvClyC5xySCwHHrXH6oskjqERc4xnn+VWtOLllExYt90dSR703BNXEpNHsGm3SPkk9eoGSe2P4at3mx4yOBu524rhtJuwJo84OBxuY8Z+rV1VrdE22DsDBcDnbz6HJ+ncVyzjY0W9zPnsw6grgqT65zn/PT9Kzrm0VI24OfX07fX/PQV0cZyjkkjI+ntx09cdTWfeQkkqxP1+nYVzs64yucfexcZ4xWDf2+3JI4xjiutvYV3bfXB4/z/AJ9qxbmMcgZAxwP8/wCelbQlYipG5y1kxttSaIN8k/HH94dP0yK7rRbeOCBpX68cnt6H88VxF/iK4ilXqkisPwNal1rUk37u2zgcDHQCvrsqqudHlfQ+Pzajy1rrqdZdagsZUROOmCxHQdselZhla4fJZnAGMmqenWjSkSXUhPtngVfnuY7ZdseAcEY9K9ZI8i1tiK4fy05Yjsazmcu+SM/Wh3e4fq2KmihfbwenUGgpKxCwIUgAjNS2SADJ5/rROhyEPUmrsceIjjt0J9aaBsryDJ4zwaKcw5PHPp2FFNEnpkssGMlh83J46ntn9cjp1warPfhBhTjAyCD+f0/xrDlllZ/mJ5HU9fxph8zb83PGeDUKBiaFxqBfKkYUcBfaqzzFnAUY6dRg1BHjqPT0qdU8sZA+XGcev1NVawE+WK8knnp/n8P09KhAAcnnP60m5y+echuv+f8APJp7kLHjORnA/wA9/rQtAYyXexPJzjj29qhYFic8n0Jq2imQ/eHHr3pNhDpnAznjGaLiRmXlhHOOQQfX0rntQ0hkLZyR2/8Ar12gQgD1zwD/AC96ieESFgQuPc0blxm0eb3Gm8Hg4I9Kqr9otvlXLxjs3b8a9GfSQ5BAC5zWLeaQ8bksgGe+f5/571jUpxmrSR0067i7pnOW93E5UEhX/uvxn8ehq5BIFfaF4Pb3qK60tmGCueOcCqCWl3bMFT548/dPzD8O/wCVedWy2L1gepRzFr4jdj2liTnB74pxiQDcrj0wOay1vZbdP3oKBuSDyKsQ3sbLwcn1ryquFqU3qj06eLhU2Zt2EjKwD4x04ArpbK7A2KnqBjc3P5Hp+FcV9q2DKgkHjgVPZ3WWA/vdjx+lcU6VzshVTPQre5ZmYnAZsYKqBx6/3iP85pt4zbixyvTAHf69/wCdc5Y6msUZD8/NuABxzx07foasTaoZVBxjvhRwP/r84rklTaOyE0yK9b1ADDv7ZrFvDwTznuD1q7cTKcNuHpj04rKvJlVHGckdc04QbY51Ekc/qYEkoTOMnrVzT4IIU3FuevNZlwWubg4BKr3rTsYWHDjOegr7HLaDo0ldas+OzGsqtV2eiNMXbEBIlyTx1pEtZZMM7FRjpWlZWXy/dVfpVxItnXg9hXpHl8yWxmx2QA9frUxjCJnOcDPpmtTZGoyAu0/p/n+lULpgSy8ZU9hkUE3uU4Id0rPzkcetWWXapA+h+v8A+qn20fyc5x9alcZPGPUjNMLmXcDDMRz9DRS6gQASD8w7UUykdLwMjOMD8P8APT9Kilk3NxnG3/P9f1p0uTuXJOBjn/P+eaVU2cnjA6Ht/hSMR1umFz0OM053B6HK4HI7+9LGhb5QM4HT/P8AnFWo7Y5OVxt4xjBB/wAfbrQIqqpwST6cnt/nH6e9SiMy4HUH3HT/AD2+lWWhGw9uq/8A6v8AD6VFHwMMCTk9T1/z/U+lK4DioVQASB34606IHG4ZGPTnHvUfmHdu5y3U881MrYXPHyjt25oYiORcDGOT3POaaiZycdPb/P8AkUsikkBMLnnHUUqKRyePx6e1Aya3j5AJ24G7jn8fpxTniRwQyE4GTntnjOf8/eqW1xGpI4IGd3oeufbsfwp8hVVLKDgDAOeR6/Tr/wCPCoe4XOfuNHV3+Qg5GcHOKzL/AEh4lHb/AGuuR6/QdfSuxgU7wxzhV6jt/gcUt48ccJDbDgcfXP8Aj364xQ3qXGbR5VqVi/y5BJb16kdB/L9KrppiRAvLwQM7e9dfq5jaQmMAHHAA6VzlzYT3L72YnPp0puOhtGozElvRA2F3Mn6j6VYtNQjlX91IC3GRnB/Kkn0khu+e9Up7AZ5QE+vrXDWwMJ7aHfSxk4dbnQQXXXduGRjmrZu12Y3g8dfSuJ23SHbBNMqjturRsWvllUlw5Gf9ZGrg5HoRjPevPllMm9GehHNOVao3Li+AXLNn6msmeeS4+VVIBGNxqa10xt2XDE+rDOa3LLSyRjGAK7MPldOk+aWrOPEZpOastDKsLEgAbeexxmt6yssD5h82OR0xWhb2ccabT1I69v8AP+FWFiOBk9PQdK9S1jyJTuVoR5RAXlT2Heru5GUeWud2Bgnr/n+lQyKSMKMehx+n+fSnRoTgkkBuT7/5/rQSJOp5GT9PT/PH51SILNgZxxj2q9PhgAFx+HFRwoSwAGWY9utCC42NQsYPvgf5/CmMAELegz+H+FW5EI7jggEVFKCsZwMbTj6k+n60xHNazMFRs9c0Vn+Im/esq5P4+9FF7HRFaHoBjxnIBJ6Dv/n/AApyp3GD7/5/nVplAcdsHIwMf5//AFU3G4qOMY49P8/57UrnKLCoBGMAngE9h6/5+lSmSVXGRggY+n0z9Pxx70yJMnODnHpnn/PP14qeOLGCnUjPDD9M/wA/p0zSbAgaSTcAxA9eMY9Mfp+lIzcBivByef6/r/49Vh4iG+bGFGeAR/nr39RSNGQBkY2jI9R+f0/Hnnmi4FURszAEMCepJ/matLGQpw3HbA6+n+OacEKD5sEjAIz7evT/ACOtPQLng9OR6H3x+tMkasChSDg49eR/9eiJNxyoxnn/AD6f/WqSQBFAIGD1/wAM/h29qq+aQQoHtnPB/wA/40twLihUXk4LcDsff/HtThsJfcNwPHHU/wCfX6VWgUlizNwTySOAff8Az+FVr27AjIB6nnnr/n6+lTy6jRamvhEki7ANvCsOh/2sfrXPahfvKxwQST2NRXEhdiQfyqs205HT9K0jCxSRCdzPkjjtUi9znipIYSWyenrV+FUjxlA2fXt/n/CqZVzMkjVhllyRVV9MNyTiEqvc+orpoLS2ky3mNgc+Xt5/P/PerTeWigRDj6dPapuLntscvb+G4AucMT9eBWlbaFbqeVyffitm1j3EkDg9jViUoiAEEAcZz2+n5Um+wnNsylsYY1yI0XaeMnJIwOfb/wCt70xkyenHfnpUtzPv6fdHemblXJJyeox/n/OaauK4oUADOMjr2pdhYgDBB4xj+f8AL8akt4Hn4CngZxjt/k/rWjDaIqqwIaMg+3b3745781LdguZkduWG4c9SG5wB3P06UkkTRgkhdoPT09v0PX2rWkWKPEhPBOcHnkfw/nn9Kxr2RZAVQnCk4zwT/nihajKcoLMQCP61ZhVYowcHeePoMc4/z2qBEwSSCDU4yzMgXBxxjn/Pf86oYhmDSALz07d//wBdRTjAx27cf57VNKqoxwdyjjPTj1x+tV7qQEE49zx1oQjkPEMSPJkjBDdaKdqxLTYGP6UUNHTF6HogVm6ZBbpgcfh6/j7VKAMDHzbuBkZz/j3/AFqdY9qsevHzc+v16fj6jiphFhyWHQAnI/In2+vvxUXOUhhQYUHIzwMHk/h6/wBamJ2/Nn7zDGOjEdgfX37cYFSbGG4noByT+nXHpnnAz2p00XloQQOB09c/Xt9cDGMCpvcCoV38dWJzgdx7f5zz04qVY+MA4z8w55wO/v0/Q8VBcsIwoAPAyRj8j+uf+BVUnuiBtBAGM5Ayf/r9vyqkgJbyaOJsAZJOflPT2z+f6UkNyoU4YZ6YI4/z9aynk3E5zwe9PAwCcMFPUj0q7aBYt3V4ittOBgdCf8/5FRQXse4sx4J/A81nP80nPI9ulMZcYPfoRiqtYLG5JqESoNjruxj3/wA/T1rGubgSOwLfKTk9qqurbto4z055p0cTjhxuGP09qSSQ7WGknJOePX2p0UW5h1J7YPWpoouQoyO4Iq3Db8hiAc/rVBcZBFt/hA5yQam8sbTkfj/np/8AWqeOPDDBA98U4qMMRkgZHv8Aj/ntUk3KyxsrngHvz/n/ADzVhDhFGAffvSEgEY6Z4/8Ar/570R+pJz9ece/5fpQG5dt2CW7klRn1NUbubcp78YwTn/P/ANep7mUCPp+XSs2Vg0mfTnApJdQI9xLDpx1q5aWjyOpCnBHTH+NQxIGIyMew5zWhAGfGCcZ5xxkf/X5/Smxl5IkgTLBihONw6H6++Mnn0FSSzoN/OCBgr6H39s8fQ1CZHiLbnyytjJP8XH6ZxVCacNLhCwU9OOgx/h+tZ2uILp1IwGIz268Y/wAMVUmjP8JI9sf596mZSQQSSc/kf85pAuVJGePX/P8AnFWkMropB+6VxVpVAkBOMgdScg8fy6flSQoC2Bn+fP8AnFLPwwI5AHWhgQzRsrHy+BjIB/lVC7P7pzg9e5x/ntWi75HX2JrM1FyID/M9qaGjlbs7pHbk/Sio9QfYhPQsaKZ0JHsyRoqLgqGXJyD3Pb9R69egxSPcwW6LnaSvTIxyRz9Ovv36VWnudoGGyehxxn8unXoMjn2rGubgysSTznjjt9Pz/WsVFs5jUfVPmXbhcHPy9j6j0559zVWa8aQfK2AT91en/wBb8PaqXUdcEe/I/wA//Xph6Z3c9z2x/nFWooCaa4DZ+Ynnkf5/z1qqdzEEjHripNgYHLZB6Z/z/n8aNuFGeR3FUAiKdpGOv+f8/jQ55wATkde/FTIgYkkn1qYRkjZsGcc/5/z60XAiSGMqNyjcecj/AD/nNSGBcHjPsaliwo2528c8fz/T/IqQg5+bIzg9hRcl6FL7OmDlV49R/L/PehocqABzj/P+fpWh5ak8HBzyDTCF3fKTjpyOv4/56UXC5U8k8fKOg5Ax/wDXqz5BAB/8e7n/AD1qwkWXBPCr6Hj6/wBe9WWXCEkED0PAz/X0qWxXM0x4f7ozjnp/SkVByT0HGSBipzjdg55HBHWpoYC4+XJbPB9P8O3p1ouBDHGA6bx39OW9P6/nSzqDGzhAoPOeuT6/U+2O9aRtQsjhztQfw/564/pWVqtwkMJVcls5P+fTnt60J3YzNuJssFPX3/x/SoB8zDI/LtUNvHJcOzk4B5rRgtWBBYjFXsMW3XLbcE9+e1acalETBKkZIGMEf546/wB01FaQDORye3HT8P8APSrGFBG4EqBz6H8ff8fvVEncRUlYmMoFUIp4A7D0z+dQmLO35iOOoH+c+tW2KjJZstkncP8AP+HSo2feyAINg/g55Hpx09KBlVwVdlIUKOoA4A/z/KmqNwIyM+/P+f8A69W5VB3MSSWPoBk/5/nUEUe49D/n/P6VSAkgXCtuA2993T/OM/lVeUl3Y4+Y8Ee/+cVpbBFaE8FmOORn/wDVwPX+KqG0H1IP+f8AH8qSAqbhuPoCc9sisfUpflZcnP8An/P41q3JIPocelYGoPuZ8Yx2q0i4nNay4VSAe/eioNRPnXkadiCfyopM6VsesTuXyxPynjnp/wDW6/rUSryAAMnnFPk+WNGHU8fy/wATT8YcqOBgH9DUnHcYYsKQD+X+P+eKQxfKpO4E+3v+v/66mXkZ9Gx+GRQqhplDc5XP6UdLgQqmQxxkeo/z/ninBR8uMHHYj/P+fpUgA2E4GQ/GB71LCoaZgwzx/QUgegwQnB6/Xr/n/wCsKeIuAAMAAjGOlToAQCevP4YHFSOigSYHQ8frQ2IqfMXB+YDb1547/l1Jx6mpBkKCBjnvx/np+lNueCACcbQevfGf5k1KoAjXHfAP+fwoBjYwepz0x0/XNSRxbjxhQPXpTZfkuCF+vPPORVuIAbcD+Jf6f4mhvS5JNbwAJnofr19s/p2qO+IVSd+dx6YwcY/wxV77rsoJACA5zz09evesjU2KyHacfT6mpWrAbCuSfU8Y9a2II1iUgjCp97jkHvxjjvz7DmqGkqDdwqRwf8DUlzI32Ic9GKgdscf4ClJ3dhoranfnYQMKvTjjJ/z7965i5d7qcAcIPapr6Rm3biTwP50lmihsgcitopJFLQu2kISMYxx3zjmrKnbwOMDH1pjf6pm7jGP++sfyqRANhOOR/gKm9xMvWy/usuD85AHXB7ke/O3j61JcS7N5yQzcY6449R79sD7tJakgwYPXI/T/AOuabMoKZI5A49v85qOoFIozYxgDpjt/n/GpUgKoNrMHIyG/u+hA/I96nHEasPvAcH04P+FWgoF28Y4Qlsj1+bHPrxTbBGVIjNI44VeSOeg+vX0H4U+KEru65xkk9Pz/AM9asgBo33cheg7Doen1J/Om2g3QbiMnKj9P/rCi+gFe+IxGqgAKMjI5Gf6YA59qrKP3TM2NowuPQ8n+QP51PfHM02fUn/x7H8jTJhixD/xedIM/QJTXRAY990O48kcn+f8AjXM3rYZyeT0xXRXrFWbHYH+lczrPyhwOm4j8jWqNYLUwLJRPqzHOdi9T6mipfD/Nzck9c5zRQkayep//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Osler's nodes are tender papulopustules located on the pulp of the finger in a patient with bacterial endocarditis caused by Staphylococcus aureus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles V Sanders. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_10_28847=[""].join("\n");
var outline_f28_10_28847=null;
